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Background: Ischemic preconditioning is a protective mechanism whereby 
repetitive transient ischaemia confer protection against the subsequent prolonged 
lethal ischaemia that is observed during myocardial infarction. This protective 
phenomenon that lessens myocardial infarction can be mimicked by the cytokine 
tumor necrosis factor alpha (TNFa) but the signalling pathways involved still 
remain unclear. We hypothesized that the signal transducer and activator of 
transcription 3 (STAT-3) plays a critical role in both ischemic and TNFa 
preconditioning. 
Methods: To explore this hypothesis, we first generated cardiac specific STAT-3 
deficient mice using Cre-LoxP technology. Cardiomyocytes, isolated from 
wildtype (WT) or cardiac specific STAT-3 knockout mice (KO), were subjected to 
26 hours of simulated ischaemia followed by 2 hours of reperfusion. Myocytes 
were preconditioned either with 30min of hypoxia or TNFa (O.Snglml). An 
inhibitor of STAT-3 (AG490; lOOnM) or an inhibitor of PI3KJAkt (wortmannin, 
lOOnM) was given during the preconditioning stimulus or at the time of 
reperfusion. Cell viability was assessed via cell morphology and trypan blue 
exclusion. Similarly, isolated langendorff perfused hearts (mice or rats) were 
SUbjected to a regional ischaemialreperfusion insult and were preconditioned with 
either short periods of ischaemia or exposure with low dose of TNFa (O.Snglml). 
Infarct size was measured using triphenyltetrazolium chloride technique. Western 
blots analysis were performed to evaluate the activation ofSTAT-3 and Akt during 
the preconditioning stimulus or at the time ofreperfusion. 
Results: In isolated cardiomyocytes and in an isolated mouse hearts, we 











mice failed to preconditioned with or an ischemic stimulus. In addition, 
both were with an 
activation during the preconditioning at the time of 
reperfusion the wildtype mice and further investigations conducted with STAT­
3 inhibitors demonstrated that this was required preconditioning to 
cardioprotection. In preconditioning, our data suggest the 
possibility a cross-talk activation activation. 
,...",nfy"".. we showed that the cal·dH)m·ot<~ctl afforded is independent 
activation of the classic pro survival kinase Akt, therefore suggesting that 
can via a novel and Akt-independent pathway. 
this we delineated a cardioprotective 
myocardial infarction. pathway involves the activation of 























The heart is a highly specialized pump with the functional role of transporting 
blood throughout our body and maintaining a healthy circulatory system. Under 
physiological circumstances, the heart pumps 7 500 litres worth of blood a day 
that equates to 136 875 000 litres over the course of a healthy 50 years 
(http://kidshealth.orglkid/body/heart_noSW.html). The efficiency of this pump 
would tend to diminish as we get older and the negative accumulative effects 
associated with an unhealthy lifestyle, will result in premature death due to 
cardiovascular disease. 
Cardiovascular disease is the end point of an accumulation of "risk factors". 
These factors, which increase an individual's risk of entering a diseased state of 
the myocardium (heart muscle), include smoking, high cholesterol levels, an 
unhealthy diet which can lead to obesity culminating in type II diabetes, elevated 
blood pressure and lack of sufficient physical activity 
(http://www.arnericanheart.org). According to the World Health Organisation, 
coronary heart disease accounted for 13% of all deaths worldwide in 2002 
(http://www.who.int/enl).By 2020, heart disease and stroke are predicted to 
become the leading cause of both death and disability worldwide, with the 
number of fatalities projected to increase to 24 millions a year by 2030 
(http://www.who.int/enl). The statistics in South Africa show a daunting 6.3 
million people suffering from hypertension (chronic long tenn elevation of blood 
pressure), 4.5 million with high blood cholesterol level, 1.5 million with Type II 












The above-mentioned risk factors progressively lead to the narrowing of the heart 
arteries. As a result, the flow of oxygenated blood to the cardiomyocytes (muscle 
cells of the heart) is reduced resulting in an ischaemia. An ischaemia is defined as 
the insufficient amount of oxygenated blood flowing to the myocardium to sustain 
its oxygen and nutrient requirements (http://www.americanheart.org; Opie 2004). 
Ischaemic heart disease is an outcome of coronary artery disease and ultimately 
ending in heart attack. 
The majority of cell death during prolonged coronary occlusion occurs via 
necrosis (cell death resulting from irreversible damage to the cell) (Harper et al. 
2003).In order to salvage the myocardium, the occluded artery can be re-opened 
thus allowing the reperfusion of the heart. However, if not controlled correctly, 
reperfusion itself contributes towards cellular damage and myocyte death in an 
apoptosis (programmed cell death which can be reversed) dependent manner. This 
is termed reperfusion injury (see review by Yellon et al (Yellon et al. 2003)). 
In this setting of ischaemialreperfusion injury, it is imperative to understand the 
biochemical functioning of the heart and how it can intrinsically protect itself, in 
the perspective of developing new and novel therapies against ischaemic injury. 
1. Cardiac preconditioning - A biological mechanism of cardioprotection 
In 1986, while performing experiments on adenosine triphosphate (ATP) levels in 
the failing canine heart, Murry et al came across a biological mechanism of 
instinctive cardioprotection whereby the ischaemic myocardium was protected 











al. 1986). They observed that 4 cycles of 5 minutes ischaemiafreperfusion prior to 
a 40 minute ischaemia lead to a significant improvement of the viable cardiac 
tissue and a reduction in the infarct size. This experiment demonstrated that brief 
episodes of ischaemia and reperfusion, preconditioned the heart against sub-lethal 
ischaemia. This type of cardioprotection was then described as ischaemic 
preconditioning. 
Preconditioning-like protection can also be induced by other means of chemical 
and physical stimuli including hypoxia (Bruer et al. 1997; Milano et al. 2002; 
Uchiyama et al. 2004), thermal stress (Heads et al. 1996), stretch (Iliodromitis et 
al. 2002) and pharmacological agents including adenosine (Auchampach et al. 
1993), bradykinin (Goto et al. 1995) and o ioids (Cohen et al. 2001). 
Preconditioning protects the myocardium by reducing the infarct size (Jonassen et 
al. 2001; Lochner et al. 2003a) and/or improving the contractile function of the 
heart (Liu et al. 2002; Lochner et al. 2003b). Although first observed in the heart, 
the phenomenon of ischaemic preconditioning has successfully been 
demonstrated to occur in mUltiple tissue types, including the skeletal muscle 
(Kohin et al. 2001), the brain (Kis et al. 2003), the liver (Ates et al. 2002; Koti et 
al. 2002) and the kidneys (Kosieradzki et al. 2003) of a wide variety of mammals. 
These widespread observations of induced protection due to ischaemic 
preconditioning suggest that it may be an evolutionary conserved cell survival 












1.1 The "first" and "second" windows of protection 
Further studies revealed that the protection observed in ischaemic preconditioning 
is the first of two "windows" of protection from sub-lethal ischaemia occurring in 
the myocardium. The first window of protection or Classical Preconditioning 
occurs up to 3 hours following a preconditioning stimulus (Figure 1). The second 
window of protection (SWOP) or delayed protection, was observed to occur 24­
72 hours following the ischaemic preconditioning stimulus (Yell on et al. 1995; 
Baxter et al. 1997; Ebrahim et al. 2001) and is protective to a lesser extent when 
compared to the first window (Figure 1). In this thesis, only the classical method 
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Figure 1: The "flrst" and "second" windows of cardioprotection (modified 











1.2 The trigger and mediator phases of cardiac preconditioning 
In all biological systems, a cascade of signal events is crucial to attain a desired 
outcome. Preconditioning the heart requires the initiation of one or possibly more 
signals, which promote the activation or the transcription/translation of proteins 
that are mandatory to protect the myocardium from sustained ischaemia. Over the 
past few decades, a large amount of work has been done to delineate these 
signalling pathways but the mechanism of protection has not yet been completely 
elucidated. 
The action of signalling molecules involved in cardiac preconditioning can be 
divided into 2 phases (Figure 2): 
1. 	 The trigger phase: This period occurs between the moment the heart is 
subjected to a preconditioning stimulus and the beginning 
of the index ischaemia. Preconditioning triggers initiate a 
change in the physiology of the heart rendering it more 
resistant to the forthcoming ischaemiaireperfusion injury 
(Yellon et al. 2003). 
2. 	 The mediator phase: This phase begins at the start of index ischaemia and 
ends with the termination of reperfusion. The signalling 
molecules here form part of a signalling cascade which 
terminates with the activation of end effectors. 
The end effectors of preconditioning are currently unknown. Exacerbating this 











identified. Some signalling molecules are common to both the trigger and the 
mediator phases which may suggest a convergence at a point, in the signalling 
pathway leading up to cardioprotection. 
Mediator Phase 
PCfTrigger Phase ~______.. ......______A~ ....... 

~r , 
Index Ischaemia 9 ; 
Preconditioning occurs either via one or 
more cycles of I/R or via pharmacological 
administration of PC mimetics. 
Figure 2: The preconditioning/trigger and mediator phases of 
cardioprotection. Cardiac PC can be divided into a PC phase that occurs prior to 
index ischaemia and a mediator phase that occurs from the index ischaemia 
onwards. I/R- ischaemia/reperfusion, PC -Preconditioning. 
a) Preconditioning with ischaemia 
The mechanism by which ischaemic preconditioning protects the heart 1S 
incompletely delineated. By subjecting the heart to transient bursts of 
ischaemiaireperfusion, signalling molecules such as adenosine, bradykinin, 
norepinephrine and opioids are released. These molecules bind to the receptors 
located at the cell surface membranes and initiate the preconditioning cascade. 
Using different animal species, experimental models, protocols and endpoints, the 
literature reports some controversial findings. Ischaemic preconditioning is 











perfusion model (Langendorf£). The severity of ischaemia can vary between 
regional ischaemia (ligation of the left coronary artery) or global ischaemia and 
the endpoint can be functional recovery of infarct size. Lochner et al have 
compared these different models and they concluded that infarct size analysis was 
a more reliable endpoint than functional recovery (Lochner et al. 2003b). 
The number and duration of ischaemia/reperfusion cycles employed to induce 
cardioprotection have an additive effect culminating in protection. Using two 
conventional models of ischaemia preconditioning in the isolated rat heart, Awan 
et al observed varying degrees of protection (A wan et al. 1999). The first model 
with one cycle of 10 minutes ischaemia/reperfusion improved functional recovery 
by 157% while 4 cycles of 5 minutes ischaemia/reperfusion improved functional 
recovery by 440%. 
Similarly, inhibitors of cardiac preconditioning may prevent cardioprotection 
from a single ischaemia/reperfusion cycle only. Hence, Goto et al demonstrated 
that inhibition of bradykinin could prevent cardioprotection from one short cycle 
of ischaemia/reperfusion but not from several cycles (Goto et al. 1995). It was 
suggested that a preconditioning threshold had to be reached for cardioprotection 
to occur. The number of ischaemia/reperfusion cycles had to be increased to 
overcome the action of the inhibitor. In support of this data, Morris et al (Morris 
et al. 1997) demonstrated that individual administration of either a "sub­
threshold" ischaemic stimulus or insufficient concentration of an angiotensin 
converting enzyme (ACE) inhibitor failed to precondition the myocardium. 
However, by concommitent addition of the two stimuli lead to cardioprotection 











Ischaemic preconditioning can be mimicked by means of pharmacological agents. 
Exogenous administration of adenosine (Cain et al. 1998), acetylcholine (Mullane 
et al. 1995), bradykinin (Goto et al. 1995), endothelin (Erikson et al. 1996), 
opioids (Patel et al. 2002),cytokines (Smith et al. 2002b) and ~ adrenergic 
agonists (Lochner et al. 2003b) have all been shown to confer protection in a 
broad spectrum of animals. The relative concentration and time of administration 
of these preconditioning agents may vary between species (see review (Yellon et 
al. 2003)). Pharmacological preconditioning can be a useful tool for the 
understanding of intracellular mechanisms involved in this complex phenomenon. 
b) GI-protein coupled receptors 
Receptors of triggering agents of cardioprotection, such as adenosine, bradykinin 
and noradrenalin are coupled to heterotrimeric guanyl nucleotide binding proteins 
(G proteins) (Thornton et al. 1993; Schultz et al. 1998). These proteins mediate 
the preconditioning signal from activated receptors to downstream targets that 
transmit the cardioprotective signal intracellularly. G-proteins are located within 
the lipid bilayer of cells and they can move freely, thus allowing a multitude of G­
proteins to be activated by a single occupied receptor complex (Lubert 1988). 
Two sub-types of G-proteins have been identified. The G stimulatory protein (Gs), 
which is cholera toxin sensitive, and the G inhibitory (Gj), which is pertusis toxin 
sensitive. Both are constituted of three subunits, Ga (45 kD), G~ (35kD) and Gy (7 
kD). In the inactive state, Guanosine Diphosphate (GDP) is bound to the Ga 
subunit thereby facilitating the interaction of the three subunits. In the presence of 
an occupied receptor, GDP is exchanged for guanosine triphosphate (GTP) at the 











separating the Gu-GTP bound subunit from the GfYr subunits, thus activating this 
signal transducer. The activation is reversed when the bound GTP is hydrolysed 
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~ 
+
oD ~TPa Active state 
P, H2O 
Figure 3: G-protein activation. G-proteins consist of 3 subunits, Ga, G~ and a 
Gy subunit. When inactive, GDP binds the complex together. In response to an 
extracellular signal, GDP is exchanged for GTP at the Ga-subunit causing the 
G-protein complex to become active after disassociation. The signal is switched 
off when GTP is hydrolysed to GDP. GDP- Guanosine diphosphate; GTP -
Guanosine triphosphate. Adapted from Grisham (Grisham 1997). 
Stimulation of the Gs-protein complex will activate adenylate cyclase resulting in 
the catalytic formation of the second messenger cyclic adenosine monophosphate 
(cAMP) from adenosine triphosphate (A TP). An excessive concentration of 
intracellular cAMP is detrimental to cardiac function (Harnmarberg et at. 2004). 
Once Gj-protein is activated, the GfYr subunits are released and they bind to the 
Gsu-GTP bound subunit preventing it from inducing cAMP via adenyl cyclase 
activation. The role of the Gj-protein in cardioprotection has been intensively 
studied and proven to be controversial. Adenosine accumulates rapidly in the 
ischaemic myocardium and signals via these Gj-proteins to activate the stress 











been demonstrated to block the effects of preconditioning when administered 
prior to the ischaemic preconditioning stimulus in rabbits (Thornton et at. 1993). 
In addition, stimulation of the Gi-protein coupled muscarinic (M2) receptor with 
carbachol, induced preconditioning-like protection from an ischaemic insult 
(Thornton et al. 1993). In contrast, studies in the rat myocardium have generated 
controversial data with evidence both for (Parratt et at. 1993) and against (Cave et 
at. 1993; Liu et at. 1993) the involvement of Gi-proteins in cardioprotection. The 
activation of many Gi-protein coupled receptors has been shown to be able to 
induce preconditioning-like protection from ischaemia including bradykinin and 
adenosine receptors (Fryer et at. 2002) . 
Gi-protein activation is followed by the activation of phospholipase C (PLC) and 
phospholipase D (PLD) (Guillon et at. 1992). PLC degrades the membrane 
phospholipid phosphatadylinositol 4,5 bisphosphate (PI2) to inositol 1,4,5­
trisphosphate (IP3) and 1,2-diacylglycerol (DAG) (Lubert 1988; Yell on et at. 
1998). DAG in-tum activates protein kinase C (PKC) facilitating its translocation 
and induction of cardioprotection (Figure 4). PLD degrades other membrane 
lipids such as phosphatidy1choline, which is metabolised into DAG via a 
phosphohydrolase. Usually, the production of DAG is short lived, peaking within 
30s. In contrast, PLD-mediated formation of DAG takes longer, facilitating the 



















Figure 4: Signalling cascade in cardiac preconditioning: Activation of 
protein kinase C (PKC). G-protein coupled receptors are activated in response 
to a PC stimulus culminating in the activation of PKC via DAG formation by 
both PLC and PLD. DAG- Diacylglycerol, GTP- Guanosine triphosphate, IP3­
Inositol 1,4,5-triphosphate, PLC and PLD- Phospholipase C and D, PC­
Preconditioning, Pb- Phosphatadylinositol 4,5 bisphosphate. Adapted from 
(Grisham 1997). 
c) Protein kinase C (PKC) 
PKC is an important mediator of cardiac preconditioning (Fryer et al. 1999). It is 
a serine-threonine kinase that functions as an intracellular signalling peptide for 
many growth factors, such as angiotensin, endothelin and vascular endothelial 
growth factor (Naruse et al. 2000). PKC can also be activated in response to 
stress-related factors such as ischaemia, hypoxia and oxidants (Pain et al. 2000). 
Binding of DAG to the regulatory subunit of PKC causes a confonnational 











receptor activated C kinase, "'U : • .....,.."-. within the cells. RACKs are bound to 
intracellular structures/organelles and form docking for activated 
PKC, functionally bringing this peptide into proximity of its target substrate 
proteins. To 12 isoforms of have been identified (Naruse et 2000) 
and can be divided into groups: 
1. 	 Conventional PKC's - which are calcium and DAG dependent for their 
activation. include the <1, ~J, and y 
2. 	 Novel PKC's which are calcium independent but DAG dependent. 
These include the e, 11 and eisoforms; 
3. 	 Atypical PKC's - which are calcium and independent regarding 
activation. These include the ~, and vA, isoforms of 
Activation and subsequent translocation of has been ""',,,urn to be necessary 
the protective preconditioning et al. 1997). 
Inhibition of PKC with staurosporin, polymyxin B or 
prior to and/or ischaemia, abrogates the protection with 
preconditioning most models (Speechly-Dick et 1994; Pain et al. 
2000; YeHon et al. 2003). Supporting findings, direct activation of PKC, 
either with DAG analogue 1,2-dioctanoyl-sn-glycerol (Speechly-Dick et al. 
1994) or the agonist phorbol acetate (Gray et al. 1997) both induce 
preconditioning-like protection in isolated rat hearts and myocytes, 
respectively. In inhibition of microtubular with 











afforded by ischaemic preconditioning, supporting the concept that PKC 
translocation is essential for protection (Liu et al. 1994). 
Of the above-mentioned isoforms, PKC€ and PKCu play active roles in 
cardioprotection. Following an ischaemic stimulus, PKCu is activated in the dog 
heart (Naruse et al. 2000) while PKC€ is activated in the mouse, rat, rabbit and 
pig heart (Gray et al. 1997; Ping et al. 1997; Liu et al. 1999). In addition, 
Mochly-Rosen's group has been able to induce cardioprotection in an in vitro and 
in vivo settings of coronary artery ligation in mice and pigs using a specific PKC€ 
agonist (Liu et al. 1999). 
d) Mitogen activated protein kinases (MAPK) 
Intracellular signal transduction is also mediated by tyrosine kinases. These 
proteins induce gain or loss of function by phosphorylating target proteins on 
tyrosine residues. Tyrosine kinases were first proposed to have a protective role 
by Maulik et al (Maulik et al. 1996). Administration of genistein, a broad­
spectrum tyrosine kinase inhibitor, blocked protection from ischaemic 
preconditioning. Interestingly, PKC activation was impaired suggesting that 
tyrosine activation occurred upstream of PKC. The role of tyrosine kinases in 
preconditioning was confirmed by Baines et al in the rabbit heart (Baines et al. 
1998). However, they suggested that the tyrosine kinase activation occurred distal 
to or even possibly in parallel to PKC activation. Since then, several studies have 
suggested that the tyrosine kinases act in parallel with PKC (Vahlhaus et al. 1998; 











MAPK are a family of intracellular tyrosine kinases which are activated in 
response to external stimuli and cellular stresses such as heat shock, stretch and 
ischaemia (Michel et al. 2001; Steenbergen 2002). MAPK activation is the final 
step of a tightly regulated signalling cascade which is initiated via the activation 
of a MAPK kinase kinase (MKKK). These in turn activate a MAPK kinase 
(MKK), which finally activate the MAPK (Widmann et al. 1999; Michel et al. 
2001; Steenbergen 2002) (Figure 5). 
Extracellulr Stimulus 
/l~ 
Q E R K 
Figure 5: General MAPK signalling cascade. MAPKKK are activated in 
response to external stimuli. They in turn phosphorylate and activate the 
MAPKK which then activate specific MAPK. ERK- Extracellular signal-regulated 
kinase, JNK- cJun NH2-terminal kinase, MKKK- MAPK kinase kinase, MKK­
MAPK kinase, MAPK- Mitogen activated protein kinase. 
The MAPK activate transcription factors, both in the cytosol and nucleus, as well 
as other kinases and structural or functional proteins. To date 14 MKKK, 7 MKK 











et al. 2001; teerlbereen 2002). of the MAPK sub-families are 
thought to have a role in preconditioning: 
1. p38 MAPK family p38 a-MAPK, p38 ~-MAPK, p38 y-MAPK and p38 
2. cJun NHz-terminal kinase (JNK) family - JNKl, andJNK3. 
3. Extracellular signal-regulated kinase (ERK) family - ERK 1 
i) p38MAPK 
p38 MAPK as a mediator of preconditioning is controversial. 
Early in preconditioning noted p38 MAPK was phosphorylated 
following an ischaemic preconditioning stimulus and during index "'....lH.""l!! 
in rats (Maulik et al. 1 Yell on et 2003) and rabbits (Weinbrenner et al. 
1997). addition, activation of MAPK with anisomysin, a dual 
activator both p38 and JNK, been demonstrated to induce 
from ischaemia/reperfusion injury and protection was 
abolished using the p38 inhibitor 203580 (Lochner et al. 2003a). p38 
MAPK is thought to protection MAPK-activated protein kinase 2 
(MAPKAP2) (Figure 6) which will activate heat shock protein 27 (Hsp27) 
et 1998). promotes assembly which increases 
tolerance of the cytoskeleton to stress. Iscna<~mlIC 
anisomycin have all reported to MAPKAP2 activation and 
protection from ischaemia via MAPK (Maulik et al. 1996). 











et al. 2003) and rats (Fryer et al. 2001a) following an ischaemic preconditioning 
stimulus. In direct contradiction, attenuation of p38 MAPK activity was 
associated with improved recovery (Marais et al. 2001). Similarly, SB 203580, 
has been demonstrated to induce cardioprotection in rats and pigs (Steenbergen 
2002) and to inhibit p38 MAPK, but not JNK 112 in a dose dependent manner 











---.~ Cardiac Protection 
Figure 6: Signalling cascade in cardiac preconditioning: Activation of the 
MAPK family of tyrosine kinases. The MAPK are activated following a PC 
trigger. This occurs via the intracellular signal mediators ROS, PKC and 
through the MAPK signalling cascade. The MAPK activate MAPKAP2 inducing 
cardioprotection. MAPK- Mitogen activated protein kinases MKK- MAPK kinase, 
PKC- Protein kinase C, MAPKAP2- MAPK-activated protein kinase 2, PC­











undertaken into ofp38 MAPK 
cardioprotection, substantial ambiguity remains. contradictive findings 
due to the diverse models used, the in the biochemical 
methods used to determine p38 MAPK activation and the reported variable effects 
MAPK activators inhibitors in the Furthermore, the period 
during which p38 MAPK IS activated may a vital role in determining 
whether cardioprotection occurs. Using an isolated rat model, .LJV..,HJl.V. et 
have demonstrated that p38 MAPK activation is required to 
cardioprotection but attenuation during ischaemialreperfusion is needed a 
in infarct (Lochner et al. 2003). In the various isoforms 
p38 MAP, p38 or ~, may have For example, in 
p38 a-MAPK is while p38 IS 
anti-apoptotic (Michel et al. 2001). 
cJun NHrterminaIIllUlJU""'''' (JNK) 
is a stress responsive .".u""..., of which 3 JNK1, JNK2 
are known to exist. and JNK2 are "'..'.!il(';n;u ............. J' expressed in the 

are involved in cardioprotection. JNK is by cellular stresses such as 
heat, osmotic shock, cytokines and ischaemialreperfusion (Armstrong 2004). 
have shown is activated an ischaemic preconditioning 
or pharmacological et 2000). JNK 
phosphorylation decrease at following an 
preconditioning (Sato et al. 2000), suggesting that may not 
attenuate reperfusion injury. Pharmacological preconditioning with anisomycin 











et al. 2001a). induced cardioprotection could be abrogated 
a selective JNK inhibitor (Fryer et al. 200 JNK been 
implicated as a downstream signalling intermediate in PKC mediated 
cardioprotection. Subsequently, up-regulation of PKCa transfection studies 
increases JNK eXJ)re~iSl0in (Ping et al. 1999). 
Shao et al provided new that prevents from 
hypoxiaJreoxygenation injury contributing to activation the pro-survival 
kinase Akt reoxygenation (Shao et 2006). they revealed a 
JNK phosphorylation on Akt that they suggest is required for the re­
activation Akt at reoxygenation for cardioprotection to occur. 
iii) Extracellular signal-regulated kinase (ERK) 
The role ERKI and ....,................... (ERK 1/2) has been eXlenSIve studied as a 
mediator cardioprotection. ERK is phosphorylated and activated in 
preconditioning period foHowing an ischaemic (Kim et al. 1999; et al. 
2001 b) or pharmacological preconditioning ofthe opioid 
receotc)r agonist, TAN-67 «Fryer et al. 2001b) also see by Hausenloy et al 
(Hausenloy et al. 2004b)), Transforming Growth Factor-~1 (TGF-~l) (Baxter et 
2001) and cardiotropin-l (Brar et al. 2001) nl"r'p~H:p ERK 112 phosphorylation 
levels prior to index ischaemia. These phosphorylation levels decrease during the 
index ischaemia ERK112 activation once enhanced at the time of 
reperfusion review (Hausenloy et 2004b )). Inhibition of 112 
activation during preconditioning phase with PD 98059, results in a loss 











manner response to PKC activating phorbol esters linking 112 as a 
downstream mediator PKC induced cardioprotection. Similar to MAPK, 
ERK 112 activates the cardioprotective Hsp27 via MAPKAP2 improving 
tolerance the cytoskeleton to stress (Kim et 1999) 6). 
More recently, 112 has implicated, with as a major component of 
so-called "Reperfusion Kinases" (RISK) pathway 
(Hausenloy et al. 2004b). RISK pathway stipulates that activation of pro­
survi val kinases, 112 Akt, during early reperfusion attenuates 
reperfusion induced cell death via upregulation of anti-apoptotic mechanisms 
(Hausenloy et al. 2004b). Supporting this, ERK phosphorylation levels have 
been to be during early r",.. ,,,, .. ,n, following an orU"VA.BA'" 
pharmacological preconditioning stimulus (Mocanu et al. 2002). In addition, 
direct activation 1 by staging reperfusion (staged reperfusion) with 
pharmacological agents such as Insulin-like Growth Factor-l (IGF-l) (Parrizas et 
al. 1997), (Baxter et al. 2001), cardiotropin-l et al. 2001), 
~ ..npr(7 et al. 2004), Fibroblast Growth Factor (Buehler et 
2002) or urocotin (Buehler et al. 2002) can induce cardioprotection (see 
review Hausenloy et al (Hausenloy et al. 2004b»). inhibition of 
ERK 112 activation during early reperfusion, with the inhibitor PD 
abrogates cardioprotection following ischaemic or pharmacological 











e) Phosphatidylinositol-3-kinase (PI3K)/Akt pathway 
PI3K1Akt pathway IS a pathway, which attenuates 
SyruneSlS, and glucose transport the myocardium regulates 
(Murphy et al. 2003). as protein B IS a 
serinelthreonine kinase that IS activated upon the 
phosphatidylinositol-3-phosphate (Murphy et al. 2003). been 
shown to mediate its function as a pro-survival kinase via the phosphorylation and 
inactivation pro-apoptotic kinases, bcl-2 death 
"F,VU..,. (BAD), glycogen kinase-3~ (GSK-3~) and activation anti-
target"'....,.,..... t",-,,, transcription T",,,,,rn..e as "'", .. UL..... (mTOR) 
p70s6 kinase (Jonassen et al. 2001) 7). This kinase is 
study as it has been conclusively shown to play a central 
development of acute cellular adaptation to ischaemic and hypoxic stress as well 
as being critical as both a and mediator in ischaemic preconditioning. 
studies have activation following or 
preconditioning ",,,IHUH as acetylcholine, """\.<1'-''',"'1.1 1 and 
bradykinin (Mocanu et et al. 2004b). all 
of this Akt activation, trigger phase, with the "''-'''~'''L1 PI3K 
inhibitor wortmannin, a loss of the protection with 
ischaemic and pharmacological preconditioning (see review Hausenloy et al 
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Figure 7: Signalling cascade in cardiac preconditioning: Activation of 
PI3K/Akt. Akt is phosphorylated and activated following a preconditioning 
(PC) stimulus. Akt phosphorylates numerous downstream peptides leading to 
cardiac protection via the inhibition of apoptosis. GSK-313- Glycogen synthase 
kinase-313, PI3K- Phosphatidylinositol-3-kinase, mTOR- mammalian target of 
rapamycin. 
As previously mentioned, Akt is a major signalling molecule of the "RlSK" 
pathway. Similar to ERK, Akt phosphorylation levels have been shown to 
increase during early reperfusion following an ischaemic or pharmacological 
preconditioning stimulus (Hausenloy et al. 2002). In addition, staged reperfusion 
via pharmacological activation of Akt at the onset of reperfusion rescues the 











al gIven at onset of reperfusion, induced protection following 
ischaemia rat in isolated following hypoxia (Jonassen 
et al. 2000). This protection was attributed to the activation of the PI3KJAkt 
pathway. Interestingly, if was following 15 minutes 
reperfusion, no protection ensued. These results clearly indicate that 
pharmacological early reperfusion (within the 15 
minutes of reperfusion) mediate a cardioprotective-signalling v"""vU,",'''' (Jonassen et 
al.2001). 
t) KATP channels 
channels are ATP potassium conducting channels. are 
normally closed or inhibited at physiological ATP levels they open as 
levels drop et al. 1997). channels playa key role in preconditioning, 
with activation in cardioprotection (Forbes et al. 2001) and inhibition 
negating induced protection (Auchampach et al. 1992). Although a large number 
studies have elucidated the regulation and manner which are 
the true physiological determinants of channel are not known 
(Flagg et 2005). 
distinct populations of KATP exist within the cardiomyocytes, the 
sarcolemmal and the mitochondrial KATP pools (Kukreja et 1990; Kim et 
1 Each displays properties and can activated or inhibited using 
specific pharmacological compounds. though pharmacological tools 
exist, a amount of controversy exists as to which channel is important 












i) Sarcolemmal KATP channel 
The sarcolemmal channel opening occurs following hypoxia or ischaemia 
(Sakmann et 1983). was hypothesised to the myocardium and 
infarct by preventing excessive calcium from the myocytes 
and reducing calcium overload during reperfusion 
(Gross et al. 1999). Since, (lP'l.I'PT!'I studies have proven the 
role the sarcolemal K ATP "'....ULU''''. in cardioprotection (Gross et al. 1999). 
However, mitochondrial KATP IS as to 
playing a protective role in cardioprotection. Specific activation of the 
mitochondrial channel, diazoxide can confer 
protection "'5""H" "",,,,,,,.1"- in the of rabbits, rats and mice (Garlid et 
al. 1997; Pain et 2000). Also, 5-hydroxy-decanoate (5HD), a mitochondrial 
KATP blocker, abrogates cardioprotection by ischaemic preconditioning (Garlid el 
1997) in above In contrast the sarcolemmal KATP HMR 
could not duplicate these .~~.~..~ (Toyoda et al. 2000). 
ii) Mitochondrial KATP Channel 
The mitochondrial channel has a role both trigger and 
mediator un""" ....." of cardioprotection. of the mitochondrial channel 
diazoxide administration is followed by a burst radical production, 
triggering the preconditioning (Figure 8) (Pain et al. 2000). Using 
radical scavengers, n-acetylcysteine or n-2-mercaptopropionyl glycine, the 
........""'-1.1'1, .......... 
 induced protection is blocked (Forbes et al. 2001). Pharmacological 











associated with a burst of free radicals all of which can be inhibited by blocking 
the mitochondrial KATP channel (Cohen et al. 2001). 
To determine the source of the free radicals within the mitochondria, the presence 
of myxothiozol, which blocks the flow of electrons from site III in the electron 
transport chain, also inhibited free radical production in preconditioning (Ludwig 
et al. 2004). This not only implicates the mitochondrial KATP channel but 
specifically suggests that the free radicals come from the electron transport chain 











Figure 8: Signalling cascade in cardiac preconditioning: Activation of the 
mitochondria. PC stimuli such as diazoxide or ischaemia trigger the release of 
free radicals from the mitochondrial KATP channel. These free radicals act as 
signalling intermediates initiating the activation of the MAPK cascade as well as 
PKC leading to cardiac protection. KATP- Potassium adenosine triphosphate, 











mi tochondrial channel has also been implicated as a mediator cardiac 
preconditioning. Phannacological activation of both PKC (Hopper et al. 2000) 
and MAPK (Yue et al. which induces cardioprotection, can be inhibited 
with indicating that mitochondrial KATP may be 
downstream to these preconditioning mediators (Hopper et ai. 2000). 
In to its as both a and a mediator of cardioprotection, the 
mitochondrial KATP channel may also function as an end effector 
support of this theory, ~"''''''F> ATP during re­
open this channel, which been demonstrated to be essential 
cardioprotection (Griffiths 2000). It is as to reason that the of 
the mitochondrial channels should be n .."t",,~t as this causes mitochondrial 
swelling and also slight uncoupling which are both undesirable during ischaemia 
(Yellon et 2003). 
Mitochondrial permeability transition pore (mPTP) 
nonnal physiological conditions, mitochondrial Inner '''~'''''JA IS 
moernrleable to most molecules. stressful It'YIcot<>n .... ,'co a non­
specific known as mitochondrial penneability transition pore, can open in 
the inner mitochondrial membrane allowing molecule that 1.5kDa to enter 
the inner mitochondria (Hausenloy et al. 2004a) (Figure 9). This causes an 
increase in osmotic of mitochondria resulting in a subsequent 
.....J, .......," of the matrix of the outer mitochondrial 
membrane (Halestrap et al. 2004). series of events result in apoptosis via the 











mPTP occurs under conditions of oxidative stress and ATP depletion. 
Consequently it is closed during ischaemia and it re-opens for the first few minutes 
of reperfusion when these conditions are present (Figure 9) (Griffiths et al. 1995). 
The core components of this pore are as follows: 
1. 	 Adenine nucleotide transporter (ANT) - which is a transporter of 
adenine nucleotides both into and out of the mitochondria. 
2. 	 Voltage dependent anion channel (VDAC) - this protein, also known as 
porin, is found in abundance in the outer mitochondrial membrane and 
usually forms a channel allowing the passage of small metabolites. 
Survival 










Closed ConfigurationOpen Configuration 
Figure 9: Induction of apoptosis or survival by the mitochondrial 
permeability transition pore (mPTP). I/R results in the formation of the 
mPTP. This allows solutes entrance to the mitochondria resulting in the 
disruption of the outer mitochondrial membrane. Subsequently cytochrome C 
is released into the cytosol initiating apoptosis. In the setting of cardiac PC, the 
mPTP remains in a closed configuration preventing cytochrome C release. ANT­
Adenine nucleotide transporter, cyt C- Cytochrome C, PC- Preconditioning, 











Cardiac preconditioning with ....,"'...... and diazoxide, mitochondrial 
channel opc;me:r. have been shown to the mPTP in closed configuration 
during reperfusion et al. 2004). mPTP 
atractyloside, a specific pore can reverse protective 
ischaemic preconditioning and diazoxide-induced cardioprotection when at 
the onset (Hausenloy et al. 2002). In addition, prevention of 
pore uu.,.",",'u with the cyclosporin induces pn::conGIUV,lLHJlJ;-' 
(Griffiths 2000). 
b) Reactive "'''''"...".... species (ROS) 
Free are molecules which an odd number 1.:>,,1""1''''''' making 
unstable and highly reactive. ROS are a type of free ......Jl"'....'" where the 
electron occurs on oxygen. ROS are formed in vivo as by-products of cellular 
enzymatic and as by-products phosphorylation 
within mitochondria (Kulisz et When produced excess, ROS cause 
intrace11u lar by oxidation proteins, lipids and acids (Guaiquil et 
al. 2004). can result in loss or of function, can be detrimental to 
the cell (Duranteau et al. 1998; et al. 2004). in moderate 
concentrations, ROS play an important role as regulatory mediators of cellular 
signalling prolce~;ses (Heads et 1996) and recently, it was demonstrated 
ROS can preconditioning-like protection (Forbes et al. 2001). 
physiological circumstances, are produced small amounts which are 
anti -oxidants as vitamin Ctargeted by 










when ROS are produced excess, physiological anti-oxidants in are 
depleted resulting an accumulation of intracellular 
hxces:sl\!'e ROS production is implicated as a cause of the damage in 
ischaemia/reperfusion injury. ROS are produced at the onset of ischaemia 
followed by a second large burst at the onset of reperfusion (Maupoil et al. 1988; 
Guaiquil et 2004). By limiting excess of ROS produced, it is to 
reduce myocardial damage. test this hypothesis, Guaiquil et al preloaded 
isolated cardiomyocytes with anti-oxidant vitamin C to decrease the ROS 
production observed in their tissue culture model of ischaemia/reperfusion injury 
(GuaiquiI et al. 2004). By lowering amount ROS produced, 
successfully increased survival rate of isolated cardiomyocytes following a 
hypoxic insult (Guaiquil et al. 2004). In addition, results were reproduced in 
vivo an experimental model of myocardial infarction. 
Paradoxically, ROS production is required to precondition the heart in • ...,,,......"'. 
and pharmacological By the transient production 
radicals, (using the Mitochondrial KATP the 
intracellular of preconditioning be initiated 
(Forbes et 2001). Furthermore, inhibition ROS production has been shown 
to avert protection from preconditioning in the rabbit, rat, mouse and chick 
cardiomyocytes(Pain et al. 2000; Cohen et 2001; et al. 2001; et 
al. 2002; et al. 2004). Downey's group used the radical 
N-2-mercaptopropionyl glycine to prevent pharmacological 











(Cohen et al. 2001). Moreover, they that 
preconditioning was not inhibited by N-2-mercaptopropionyl glycine, suggesting 
not all means of cardioprotection was dependent on ROS In 
addition to this, ROS generation has shown to activate the so-called survival 
which are important for myocardial protection, in the heart (Kulisz et al. 











2. Tumour necrosis factor alpha (TNFa) 
TNFa is a pleiotropic cytokine that was first discovered and described in 1985 by 
Old as a protein that could induce necrosis of certain mouse tumours (Old 1985). 
Two isofonns of TNF exist, TNFa and TNF~ sharing 30% of homology. TNFa is 
first expressed as a 26kDa transmembrane protein that is cleaved, by TNFa 
converting enzyme (TACE), to release a 17kDa soluble fonn allowing for more 
widespread effects of this cytokine (Figure 10) (MacEwan 2002). 
Soluble TNFa 
....................................





Membrane bound TNFa 
<"''Y''~ 





Figure 10: The production and release of TNFa. TNFa is first synthesized as a 
transmembrane proTNFa allowing TNFa to exist in its membrane bound form. 
ProTNFa is cleaved by TACE releasing the soluble form of TNFa. mRNA­
messenger ribonucleic acid, TACE- TNFa converting enzyme, TNFa- Tumour 











2.1 TNFa the heart 
is largely produced macrophages recent studies shown it to be 
cardiomyocytes (Benigni et al. 1996). TNFa expression in the heart 
not occur m a marmer and synthesis 1S at a 
level (Sack et 2000). The in the can be 
as a with adaptive and roles 
for this protein. contradictory avenues of thought are reconciled 
by first proposed Mann et al (Marm 1996), and exp,anQ(~Q by 
Sack et al (Sack 2002). proposed a acute dose of would be 
a or dose of would be maladaptive (Figure 
11). 










Figure 11: Adaptive VB maladaptive roles of TNFa. A low level of TNFa 












2.2 TNFa induced signalling 
TNFa signalling has been implicated as a mediator of diverse physiological and 
pathophysiological events including inflammation, cell survival, growth, 
differentiation and apoptosis (see review by Mann (Mann 1996)). It achieves its 
effects after binding to either one of its cognitive receptors (Meldrum 1998), the 
55kD TNFa receptor 1 (TNFR1) or the 75kD TNFa receptor 2 (TNFR2). Both 
receptors are expressed in the myocardium (Torre-Amione et al. 1995) and they 
can exist either as membrane-bound or truncated soluble forms (see review 
(MacEwan 2002)). They occur as single transmembrane glycoproteins sharing 
only 28% homology, mostly in their extracellular regions. When activated by 




Figure 12: TNFa triggered receptor activation. Binding of TNFa to its receptor 
promotes receptor trimerisation and subsequent activation of the receptors. 











cytoplasmic domains of two receptors are, in contrast, very distinct 
allowing the receptors to activate separate intracellular signalling pathways (Grell 
1 nUl"-"'" ability and molecules, 
which mediate their <3"t"t"I'tc 
studies also proposed the existence of a mitochondrial TNFa 
binding protein as well as an intracellular TNFa trafficking pathway which allows 
TNFa to transported the cell directly to the mitochondria 
(Busquets et al. 2003). 
TNFa receptor 1 (TNFRl) 
the two TNFR1 been more extem)lvlel studied. The signalling 
pathways to TNFR1 include both <lrv'.ntr.n (see 
reVIew (Sack 2002». Apoptosis is induced by adapter protein, 
death domain (F ADD) protein which recruits activates 
apoptosis initiator (Harper et al. 2003). F ADD to the 
receptor occurs indirectly through another adaptor protein, TNF 
associated death domain (TRADD) protein 13). TRADD can bind to 
two adaptor molecules named receptor-interacting protein and TNF-
receptor (TRAF-2) which may mediate the protective effect 
TNFa factor (NFKB) activation (see' ;-'V',",""o.; by Meldrum 
and (Meldrum 1998; Sack 2002», rpc'!"IPrTl Recently, the intracellular 
domain the TNFRI was shown to bind TRADD, and but not 
FADD, even though activation of F ADD is necessary for TNFa induced 











et al. 1992). This, in tum, activates the spingolipid signalling pathway and PKC 
(Wiegmann et al. 1994). 
TNFR1 TNFR2 
/ 1 




DAG ~ signalling NFkB JNK 
1 pathway 
PKC 
'" Apoptosis Cardiac protection 
Figure 13: TNFa triggered signaling pathways. The binding of TNFa to 
TNFRI leads to apoptosis via the recruitment of the adapter protein FADD 
which initiates apoptosis. TNFRI activation also leads to cardiac protection via 
the activation of PKC, NFKB, JNK and the sphingomyelin signalling pathway. 
TNFR2 activation recruits the adapter protein TRAF-2 which leads to cardiac 
protection via the activation of NFKB and JNK, TNFR. FADD- Fas-associated 
death domain, JNK- cJun NH2-terminal kinase, PKC- Protein Kinase C, NFKB­
Nuclear factor kappa B, TRAF-2- TNF receptor activated factor-2, TNFR- TNFa 











2.4 TNFa receptor 2 (TNFR2) 
contrast to pathways that are coupled to TNFR2 are 
poorly understood. but TNFR2 has been shown to recruit 
this receptor may initiate the 
protective 13). Supporting this proposal, 
genetic ~~ ..~..~ in excessive heart failure 
possibly pathway (Kurrelmeyer et al. 
2000; Higuchi et Wang et al 
(Wang et In recovery of 
VO(;anllal function when compared to their male wild-
counter 
2.5 The maladaptive of TNFa 
Earlier the development 
of myocardial Ul;)vQ.;)v. to the myocardium produces 
hypertension by et al. 1998). Abnormally high 
levels TNFa are also cardiac injury with a direct correlation 
between serum TNFa levels and and nrc)!Zn~sslon of heart failure 
(Levine et al. 1990). In the injury, TNFa levels 
are increased at Adenosine mediated 
cardiac preconditioning n ..'O·uP1nr et al. 1 Cain et 
al. 1998). 
The maladaptive effect TNFa IS empn'lSH,ea 













developed myocarditis while their wild-type counterparts remained relatively 
healthy (Kubota et al. 1997). In addition, the necessity of TNFa signalling for 
protection from ischaemic damage is observed in the TNFa , TNFR1 or TNFR2 
knockout (KO) mice (Kurrelmeyer et al. 2000). In TNFR1 and TNFR2 KO mice, 
ventricular infarct size assessed following ischaemialreperfusion was larger than 
their wild-type counter parts (Kurrelmeyer et al. 2000). Moreover, genetic 
ablation of TNFa results in a loss of the cardioprotection due to ischaemic 
preconditioning (Smith et al. 2002b). Taken together, these results suggest that 
endogenous TNFa signalling gives rise to a cytoprotective signal. 
2.6. The protective role of TNFa 
Transient low doses of TNFa administration pharmacologically preconditions the 
myocardium in a dose dependent manner (Lecour et al. 2002) in rats (Lecour et 
at. 2002), rabbits (Nelson et al. 1995) and mice (Smith et al. 2002b) (Figure 14). 
However, this protective effect is lost when TNFa is administered at a higher dose 
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Figure 14: Dose response of TNFa-induced cardiac protection. Exogenous 
administration of 0.5ng/ml TNFa (7 minutes followed by a 10 minute washout 
period) induces a reduction in infarct size in an isolated rat heart model of I/R 
injury. This protective effect is lost with higher doses. * P < 0 .05 vs control. 











In addition, IS levels from the myocardium in reSPOlnse to an 
ischaemic prt:~conal.tlOmrlg (Kurrelmeyer et al. 2000). transient 
release of may as a trigger of preconditioning. 
bodies against TNFa n"'''·U''''-.T the induced protective effect 
(Smith et al. 2002a). 
This cardioprotective Dnc;nClm<~nCfn occur in part via SDl1l1nt;[0 
(Lecour et at. 2002) and 13) (Lecour et al. 2005). n­
oleoylethanolarnine the sphingolipid pathway, or 
radical ",{,,,,'UP'n glycine attenuated the protection due to 
TNFa mediated administration also leads to 
activation (Figure 13) 2002; MacEwan 2002) and it stimulates 
release of the protective heat proteins, HSP 72 and HSP 27 
2002). 
The intracellular signal pathway of TNFa mediated protection 1;:'U'UvL1Vl1 
reqUires a to this protective pathway. 
recent studies, was found to be independent of 
MAPK activation (Tanno et 2003). One potential signalling cascade to 
investigated is the pathway that has been 
demonstrated to be and pharmacological pn::conm 
(see review Hausenloy et al et al. 2004b)). Another 











signal trarlsatlcer U~"-"U- .oJ (STAT -3), which fonus 











janus kinase- transducer and of transcription (JAK­
STAT) signalling pathway 
JAK-STAT pathway IS a novel signal transduction pathway, which, m 
to a diverse of extracellular signals, "T".!"T'~" a variety of 
numerous tissue et al. 1994). has been linked to a.....,'UUVH 
range of events including apoptosis, 
organogenesis, innate and adaptive immunity and regulation 
review (Imada et ai. 2000)). In heart, this been implicated 
hypertrophy et al. 1996), et al. 1997), 
(Mc Whinney et 1997) as well as (Hattori et al. 2001) 
and the late phases preCOfldltlOumg (Bolli et al. 2001; et al. 2001; Xuan 
et at. 2005). 
Janus kinase family (JAK) 
proteins are a tyrosine kinases composed of four members, janus 
"".1""",", 1 (JAKl), 2 (JAK2), 3 (JAK3) and 
nll>..",,", 2 (TYK2). in size from 120 - 140 kD and are 
characterised by a domain as as a pseudokinase domain nu>u"v 
which may serve as a docking site for STAT ..",·"t"",,,, revi ew Imada et 
et al. 2000)). members are constitutively associated with 
cytoplasmic receptors. When rec,en(cJr is activated, it ""'-'.u......v 
forms a dimer allowing cytoplasmic tail the a .... ~.LJu .• anJu 
JAK proteins to phosphorylate. This phosphorylation creates a docking a 
STAT protein 15). Once docked, the protein is activated by 










same STAT protein as specificity within the pathway is due to the interaction of 
the relevant STAT molecule with the receptor rather than due to the JAK which is 







Figure 15: JAK receptor dependent activation. Receptor dimerisation 
occurs in response to ligand binding. This brings the associated JAK proteins 
in close proximity allowing them to phosphorylate one another. The 
phosphorylated JAK protein also phosphorylates the cytoplasmic domains of 
their respective receptors creating docking sites for STAT proteins. Adapted 
from (Darnell 1997). 
3.2 STAT proteins 
STAT proteins were discovered while investigating the gene regulation of 
interferon type 1 (Darnell et al. 1994). They are a family of cytoplasmic 
signalling proteins that initiate gene translation. Seven STAT proteins are known 
to occur, STAT-I, STAT-2, STAT-3, STAT-4, STAT-Sa, STAT-5b and STAT6 











700 and 800 amino acids in length and conserved 












in some cells. 
Impaired Interleukin-12 






differentiation with a 
susceptibility to 
Table 1: STAT isoforms and their main function. review 
1997}) 
pY pS 
DNA Binding Domain Linker SH2Coiled-coil Transactivation 
nnm"in 
Regulates binding Mediates STAT docking 
specificity of STATs at activated receptors and 
to DNA regulatory facilitates dimerisation 
sequences ofSTATs 
for some STATs 
t'lljnf'lm..ri""ti,~n of 
dimers and site 
of arginine methylation 
Associated with regulatory peptides 	 Conserved 
important for contains Serine 
phosphorylation site of some STATs 











3.3 STAT regulation 
The regulation of STAT allows 
response to stimulation. STAT proteins are phosphorylation a 
..........,to,........ are recruited to the 
cellular membrane via a conserved src HV'.UV.1V.o:. 2 domain, which binds to 
a phosphorylated receptor (see review \,uuaua et al. 2000)). the JAK 
conserved tyrosine residue. Latent cytoplasmic 
the STAT associated then 
molecule. Tyrosine phosphorylated form either homodimers or 
heterodimers that translocate to 11L1(:<'Uj.;::' transcription target genes 
(Figure 17) (Darnell 1997). is an integral part 
of their function as nuclear occurs in the 
o."''''''''',",'''-J' 17)(Darnell 1997; presence of tyrosine 
Imada et al. 2000) . In to can be 
further phosphorylated on a via a PKCE-ERK1I2 



















Figure 17: The JAK/STAT-3 signaling pathway. JAK-2 is activated in 
response to a stimulus. Activated JAK-2 recruits STAT-3 from the cytoplasm and 
phosphorylates STAT-3 on a tyrosine residue. This allows STAT-3 to form 
homodimers and translocate to the nucleus where it up regulates transcription. 
STAT-3 is further phosphorylated on a serine residue to improve DNA 
interaction. Ser- Serine, Tyr- Tyrosine. All other Abbreviations as described in 
text. 
Activated STAT proteins are deactivated via several mechanisms. This can occur 












via the ubiquitine-proteosome In addition, two families regulators 
control the pathway intracellularly: 
1. 	 Suppressor of cytokine signalling (SOCS) members family of 
proteins pos:ses SH2 domains homologous to of specific STAT 
OJ"""n.''''",. These allow the SOCS to bind to the intracellular domain 
activated receptors f'lrp,uPf,hn STAT and subsequent activation 
review (Valentino et al. 2006». 
2. 	 inhibitors activated (PIAS) - are a family of 
proteins. influence directly 
by binding to activated STAT molecules preventing dimerisation 
deoxyribonucleic acid (DNA) binding (Valentino et 
ai. 2006». 
DNA binding 
As transcription initiators, STAT bind specifically to 
activated •.n"",..... ,",,, (GAS) on genes review Darnell (Darnell 1997» . 
are N31N4 GAA motifs. In the nucleus, STAT are 
further phosphorylated at a serine v"".....v improving binding and rate 
transcription (Figure 17). addition, proteins can nTP,r",,,t with 
factors or other isoforms to higher and 












two (i.e. the and the proteins) fonning 
JAKJSTAT signalling pathway, transduction via been 
to many reSpOll1Ses. It can be activated 
and cytokines. physiological involving STAT-3 have been 
primarily studied the of specific 
body reduction of this peptide is embryo lethal. STAT-3 been knocked 
out 
L 	 T-ceHs STAT-3 are involved In IL-6 T-cell proliferation 
(Takeda et 1998). 
2. 	 Skin cells- are involved skin 

fonnation cycle and wound healing (Sano et at. 1 

...~,."a,,", including 
3. 	 central nervons system - STAT-3 play an ......,.,'.....a'..'« role in 

via leptin signalling (Gao et al. 2004). 

4. 	 Pancreatic Jl-cells are the IH"",UIH producing cells the pancreas. 
play an important role in body weight control and glucose 
homeostasis (Gorogawa et al. 2004). 
liver -	 regulate the ext)re!;SlCm of gluconeogenic and is 
for the glucose homeostasis et al. 2004). 
6. 	 Cardiomyocytes - STAT-3 playa central role respect to 
to cardiac inflammation, acute injury and the pathogenesis of age-related 
(Jacobyet al. 2003). 











a) in the heart 
1S produced myocytes as as m fibroblasts 
and epithelial cells. It was first observed, in 1995 et at. 1 to be 
<1I'TH'<1TPrI following exposure to leukaemia inhibitory factor (LIF). LIF treatment 
causes hypertrophy (Kodama et ai. 1997), which is via STAT-3 
inhibition with AG490 (a tyrphostin that prevents JAK2 mediated activation of 
This cardiac hypertrophy was confirmed by ov(~reJmr,eSSlOn 
STAT-3 in cardiomyocytes (Kunisada et at. 2000). genetic overexpression 
of STAT-3 in induced hypertrophy and the formation of new vessels 
contributing to adaptation VV'A~H.'VAA'" of stress (Kunisada et 
2000). 
In the failing the phosphorylation of is reduced, 
suggesting a link heart decrease STAT-3 
phosphorylation (Hilfiker-Kleiner et at. 2005). mice have 
observed to develop at a earlier their cycle when 
compared to wild type counterparts (Jacoby et at. 2003). 
b) STAT-3 in ischaemiaireperfusion 
is activated as part a defence mechanism in response to ischaemia, 
hypoxia (Negoro et 2001; et at. 2005). 
an in vivo model was to be 
phosphorylated following coronary artery occlusion. (Negoro et ai. 
2001). tyrosine STAT -3 was sustained up to 











apoptotic (Omura et al. 2001). 
In support of data, Omura et al also observed an 
phosphorylation following (Omura et 2001). In 
addition, activation exerts anti-apoptotic effects cultured neonatal rat 
cardiomyocytes sUbjected to ~U',Jf>.L", metabolic inhibition and avl\.1V"'.l'" (Stephanou 
et ai. 2000). of reduces 
ischaemiaireperfusion induced apoptosis isolated myocytes (Stephanou et ai. 
genetically modified mIce, cardiac overexpreSSlOn STAT-3 protected 
induced 
ischaemiaireperfusion (Kunisada et al. 2000). the harmful burst 
which occurs at the onset of TPT\PTlnl was attenuated resulting in a 
in the part to the amplified 
production of the free radical metallothionein 1 (MTl) and 
metallothionein 2 (MT2) (Oshima et al. 2005). 
c) STAT-3 in preconditioning 
has implicated via induction 
apoptotic signals by up-regulating the expression of the anti-apoptotic proteins 
leukaemia-2 (Bcl-2) et al. 2001), Bel-xL and radical scavengers 
et ai. 2001). In STAT-3 activation is linked with 
phenomenon of cardiac preconditioning. Using an working heart model 
ischaemiaireperfusion Hattori et al(Hattori et al. 2001) demonstrated 











stimulus. This was correlated with improved J..Ull',","!',",! 
ischaemia, a decrease in the infarct size and the number 
as well as an increase in anti-apoptotic Bcl-2 and a 
(a member the Bcl-2 family of proteins which 
binds to the anti-apoptotic activity of Bcl-2). In this model, 
preconditioning stimulus was 
via phosphorylation with AG490 (Hattori et al. 
1n preconditioning, the2001). 
et al. 1995; Funamoto et 
et 2000; Brar et al. 2001) 
via STAT-3 phosphorylation (Negoro et 
upregulation of the free radical 
shock protein, HSP70 (Nelson et al. 1995; Negoro et al. 2001). 





















Ischaemic Preconditioning is a phenomenon whereby episodes of non­
lethal augments cardiac resistance towards a subsequent 
TNFa is a 1'''''&>1'''',''' cytokine which ,,,,'-'UU\,Ulj,a (Murry et 
to theIS considered as we 
emomnratea that this cytokine is to mimic the .......,..\T''Of'tn''p 
preconditioning (Lecour et at. The intracellular ou«.. ,u.,o mechanisms 
ischaemic ,..w"rAt'''"T'AT\ are unclear 
they some similar ""0"'""",«"6 pathways. the intracellular A.J ....."'..,....,.u 
mechanism cardioprotection is needed to further understanding of 
mechanism by which the can be protected ischaemiaJreperfusion 
so this knowledge can translated to the setting. 
Recently JAK2/STAT-3 pathway has suggested as a pivotal 
role in protection afforded by ischaemic preconditioning (Hattori et at. 2001). 
In a previous study that TNFa can the phosphorylation 
of TNFRI in adipocytes et 1998). 
h""r",f",,,... ,,, in this thesis, we hypothesized that: 
ischaemic and TNFa-induced preconditioning require the ",,..I'n,·:>" of 















generate a cardiac specific STAT-3 KO mouse: 
technology, we 
KO mouse as 
to 
of 
our own cardiomyocyte 
study (Section C this 
demonstrate that cardiomyocyte 
P 
STAT-3 
KO mice can 
not be preconditioned with an ischaemic or a TNFa stimulus (Section 
of this thesis), 
demonstrate that both and TNFa induced 
preconditioning require the activation of 
.I!!..:~~~~~"":;:!'!!!!:!:!.!!!~ to confer cardioprotection U"-".U'-'H E of this 
4. To demonstrate that both ischaemic and TNFa induced 
preconditioning require the activation of STAT-3 












Is STAT-3 activation required in the protection afforded by ischaemic 
and TNFa-induced preconditioning? 
Objective 1 
Generate Cardiac Wild-type Mouse Isolated Cardiomyocytes 
Specific and Isolated Rat heart. 
STAT-3 KO Mice 











PC with ischaemia, 
hypoxia 
adenosine or TNFa 
















,~I:!:!:li Preconditioning stimulus 
~ Ischaemia 
Figure 18: Hypothesis and Objectives. STAT-3 is known to be activated in 
cardiac preconditioning. We determine whether STAT-3 is activated in TNFa­
induced cardioprotection and during early reperfusion following either an 
ischaemic or TNFa preconditioning stimulus. In addition we created cardiac 
specific STAT-3 knockout mice to confirm the protective role of STAT-3 in 






















Initial at generating a traditional (whole body) STAT-3 knockout (KO) 
mouse were found to be Here, ablation of resulted 
in rapid Uv~~vl1'''l of 
days of (Takeda et al. 1997). This is of the early 
STAT-3 	 during Subsequently, further 
STAT-3 in required",a,I\.HU\J 
the of a conditional, specific, KO mouse. can be 
achieved with the Cre-Lox P of conditional genetic ablation. 
1.1 ere-Lox P technology 
The P system conditional reqUIres two separate 
transgenic mouse lines, a homozygous STAT -3 floxed mouse , F-
Floxed) an organ mouse 
(CreTfN ; T Transgene N Normal). two strains of are then 
crossed to produce the organ specific STA T-3 KO animal (CreTfN STAT-3 F1F) 
(Chien 1). 
1.2 STAT-3 floxed mouse 
Floxed are defined as animals that a specific deoxyribonucleic acid 
(DNA) ~~"'vv, the P of over P) site, into the 
line Two Lox P are integrated the DNA of protein to 
disrupted, flanking a to be Lox P sites of 2 thirteen 
base pair an 8 base asymmetric (Figure 










they serve to invert the DNA between them (Figure 20A). When arranged in a 
direct orientation they act as targets for excision of the DNA between them 
(Figure 20B) (Wagner 2000) . 
ATG TAT GC 
ATA ACT TCG TAT A TAT ACG AAG TTA T 
Inverted repeat Spacer Inverted repeat 
Figure 19: Lox P site. The DNA sequence of a Lox P site co sists of 13 base 
pair repeats which are inverted and separated by a single 8 base pair 
asymmetric spacer region. DNA- deoxyribonucleic Acid. 
A 
,-A_T_A_AC_T_T_CG_J--_{~TA~T~AC~G~AA~G=)-____[T~A~T~TG~A~A~G~C~f------I ATA TGC TTC 




DNALox P Lox P 
Figure 20: Functional orientation of Lox P sites. The orientation in which 
Lox P sites 
inverted (A) 
over P site. 
are 
or e
integrated into the genome determines whether the DNA is 











1.3 Cardiac specific Recombinase expressing mouse 
eXCISIOn a paIr of P is carried out by the 3 
~"'U~h~ P1 protein (Chien ). This directs 
removal the DNA P leaving one behind 
21 By placing control of a 
promoter, tissue specific expression of occurs and 
specific depletion the floxed protein. transcriptional activity the 
also /i;:>1r;:>...,-.~ extent to which Cre is 
and subsequently the attenuation of the protein the ST AT-3 animal. 
A high active un;'AU'-FCvA would in prominent expression Cre 
a high rate of at P site. 
as Cre cannot cross the cellular membrane, ;:>TTt'l'tc of protein 
are limited to the which it is pr duced. 
Heterozygous which had Lox P sites integrated the line 
(CreNIN STAT-3 FIN) a orientation 21 were obtained from 
of Osaka Japan (Takeda et al. 
Lox P were introduced into 21 and (non-coding DNA) 
which the phosphorylation site exon region DNA) 21 
(Figure 21 B). the Lox P are within the they have no 
on expression of STAT-3 in these Removal of exon 21 
(Figure 21 Cre and translation of 











encoding Tyrosine residue 
A I 











•a b ~ 
I I 1111 ~ ~ II 
I 
• b ~ 
STAT 3 KG 
I I 
 II 1111 ~ II 
Figure 21: deletion of STAT-3. Gene organisation in STAT 3 PIP mice before 
and after Cre mediated Exon 21 (reprefented as 0 in the figure) of STAT 3 
was flanked by identical lox P sites as Vin the sites Each site is 
a target for Cre recombinase which is used to dISrupt the STAT 3 gene, 
knocking STAT 3 out. "a" and "b" are the primers used to determine whether the mouse 












cardiac specific Cre recombinase mouse to generate our 
animal was a gift from Professor Kenneth R Chien of the"'H,-,nHhJ 
California, San Diego School of Medicine. Here, enzyme (Cre 
recombinase) was placed under control the Myosin Light Chain 2 Ventricle 
(MLC-2V) promoter ,,"V"''''-'''''F. for one the MLC-2V alleles (allele 
one 2 forms the same gene). promoter is only active in the ventricles 
of adult mice and is highly expressed ensuring an elevated of 











2.1 	Breeding strategy for the establishment of a cardiac specific STAT-3 
mouse colony 
The withstrategy to generate a cardiac 
controls is illustrated original floxed 
mice had no Cre and were heterozygous the STAT-3 floxed allele 
mice were are 
C'Tr<l'TPr1 in the punnett square (Lubey 1999) are simple to 
determine resulting variance as a result of cross-breeding) of figure 
and the distribution of in figure Of this 
F/F mice were selected establishing a 
stable 
range of genotypes, the CreNIN 
~~~u, .... colony. 
CreNiNSubsequently, mice were with the transgenic 
(CreTIN STAT-3 NIN) to FIN 
(Figure 22A). Cross these 
CreTIN and STAT-3 FIN mice 24A) in a 50/50 ratio 
these mice, CreTINSTAT_3 FIN mice were to 
F/FCreNIN (Figure and Figure to spawn 
mice, the of breeding approach 
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knockout wt mouse 
mouse 
Figure 22: Breeding strategy used for the generation of cardiac specific STAT-3 knockout 












A 	 B 
Cre"'" STAT-3'm 
Cre' STAT-)' Cre" STAT-)' 
Cre' STAT-)' ere'"" STAl'-3F -": 
Cre'STAT-)N 
III CreNIN STAT_3FIN -
Heterozygous Floxed 
NIN STAT_3 F1NCre 
3FIF• 	 CreNIN STAT_ _ 
Homozygous Floxed 
• 	 CreNIN STAT_3NtN _ 
Homozygous Normal 
Figure 23: Mouse Breeding: CreN / N STAT-3F/N with CreN / N STAT-3F /N. The 
punnett square (A) is used to illustrate the genetic distribution of the floxed 
allele in offspring of Cr eN/N STAT-3 F/ N parents . Crossing heterozygous floxed 
mice (CreN/ N STAT-3~'/ N) resulted in 3 distinctive genotypes. Homozygous floxed 
mice (CreN/N STAT-3r/r), heterozygous floxed mice (CreN / N STAT-3F'/N) and 
Nhomozygous normal (CreN / N STAT-3 N / ) mice. The resulting Mendelian ratios of 
the offspring is shown in B. Abbreviations are as defined in text. 
A 	 B 
CreTIN STAT_3 NIN 





• CreNtN STAT_3FtN 
Figure 24: Mouse Breeding: CreN/N STAT-3F/F with CreTIN STAT-3N/N • Cross 
breeding CreN/NSTAT-3F/ F and CreTIN STAT-3 N/Ngave 2 variant mouse strains (A), 
CreTIN STAT-3F/ N as well as CreN/ N STAT-3F/ N mice in equal ratios (B). 












Cre N/N STA T_3F- /r-
A 
Cre' STAT-)' Cre:-' STAT-:;:'\ 
CreTSTAT-l ' CreT"" STAT-Jr,'I\' 
Crer STAT-l' CrcT (1\ STAT_3 Fft 




• CreTIN STAT-3'1F - Knockout 
NIN FIFIII Cre STAT_3 - Wild-type 
CreNIN• STAT_3F'N 
Figure 25: Mouse Breeding: CreTIN STAT-3F/N with CreN/N STAT-3F / F. Cross 
breeding CreTIN STAT- FI N and CreN/ N STAT-3 F/F mice (A) gave rise to 4 (B) 
distinct genotypes of which 2, CreTIN STAT-3F/ N and CreN/ N STAT-3F/N were 
discarded as they did not possess the correct genetic configuration for both 
wild-type or STAT-3 KO mice _Abbreviations are as defined in text_ 
CreTIN STAT-3 FIF mice were selected and used to set up and maintain a stable 
breeding population to generate STAT-3 KO as well as littermate control mice 
(Figure 26A)_ The Mendelian STAT-3 KO to wild-type ratio of this breeding 
strategy produces 25% wild-type (CreNIN STAT-3 F1F) and 50% STAT-3 KO 
(CreTIN STAT_3 FIF) mice (Figure 26B)_ In addition, 25% of the embryos are 
homozygous for the Cre insert, i_eo, CreTIT STAT_3 F1F which is embryo lethal, as 
both alleles of the MLC-2V gene are replaced, effectively knocking this critical 











A Crel!" STAT-3F1F 
Cre' STAT-3' Cre" STAT_3 F 
Crt'Tft<C,e'STAT-," CreTCr STAT-)"" 
CreTIN STAT_3 F1F 
I STAT-3 
I CreTIN STAT-3 FIF - Knockout 
I CreNJN STAT-3 FIF - Wild-type 
CreTIN STAT-3F/F with CreTIN STAT-3F/F. The 
is illustrated in (A).used to maintain a stable mouse 
ratio is shown in (B). Abbreviations are as in text. 
2.2 Genotyping 
a) Murine Genomic DNA extraction 
DNA to genotype was the 
tails (Disch et 1996). Approximately 1 em mouse tailor 
was from mouse being 400)l1 
8.0; then(lM NaCI; 0.5M 
10% added) with K (lmg/ml) added fresh to digestion 
buffer usage. were then at The following 
day, 400)l1 of Phenol: Chloroform: Alcohol 1) (Sigma) was 
to each digested which was then and cellular 
via centrifugation, 13 000 revolutions minute (rpm) at room temperature for 











debris and upper layer DNA. the 2 
layers, contaminating bottom was removed and 
discarded barrier tips (Quality Scientific Plastics) and 200)..d of chlorofOlm 
added to remaining upper phase and tube inverted. was then 
spun in a at 13 for 5 2 separate 
occurs and the bottom phase is and while phase is 
kept. were spun at 13 OOOrpm for 10 to force remaining 
into a hA~'CA"'" of the tube. was then 
to a new sterile 1 eppendorff 50J.!l of acetate (Merck) 
and 1ml 100% ethanol (KIMIX) added the tube inverted to the 
DNA. This stringy DNA precipitate was removed, 

to a new 1.5ml eppendorff tube containing 70% ethanol to hydrate DNA. 

tube with DNA is now spun at 13 OOOrpm 10 minutes, so that 

DNA may bottom, alcohol carefully so 
as not to dislodge DNA pellet are then to air dry 1 hour and 
sterile water to DNA. 
b) Polymerase Chain Reaction (PCR) of genetically altered animals 
i) Detection of STA T -3 mutated allele 
to determine whether or not animals harboured 
floxed allele: 
: 5'- CCTGAA CAA CTG -3' ; 













: 5' CAC AGC 
 ACT Tee , . , 
IS for exon (figure 21 
protocol with primers and "b" was performed III volumes 
magnesIUm buffer (Promega), 4mM magnesium (Promega), 
Nucleotide Tiphosphates (dNTP's) 
0.625U (Promega) 
mixtures were lU'-'UVUL'-'U at 94°e for 7 minutes then run 35 cycles at for 
30 seconds, with a 10 






Figure 27: peR protocols. cycling protocols used for genotyping. 

Distinct protocols were needed for individual sets of tA) Detection of the 

STAT-3 floxed allele from DNA isolated from mouse tails using primers a+b. (E) 
Detection of the Cre with specific for the Cre and 
the wild-type MLC-2V gene. PCR- chain MLC-2V- myocyte 










ii) Detection of transgene animals 
were heterozygous 
for Cre and the MLC-2V 






The following sense 





The reaction was performed in 50~1 
Mg, ]OO~M s, 0.2flM of all 
DNA were 
cycles at seconds, 
seconds a 10 minute 
12jJ.1 of mixture was 
Bromophenol 
on a 2% (Whitehead 
bromide (Sigma) (0.1 jJ.g/ml) and 
recom binase were genotyped 
served as a control 




GGA C -3' 
containing 4mM 
1.25 U Taq and 1.5~1 
at 94°C for 4 then run for 35 
and 1 minute and 30 
at 72°C 
with 2jJ.l buffer (0.25% 
Solution, and electrophoresed 










Western blot analysis 
To the organ M~"~"'~ depletion STAT-3, the heart and 
was removed wild-type at 14 to sleep 
with carbon The tissue was washed to remove blood and freeze clamped 
using Wallenberger precooled liquid This instantly froze 
sample to 96°C preventing protein degradation. tissue was then 
at -80°C until protein was performed. Briefly, cytosolic proteins 
were pYtr~('TPt1 from myocytes or tissue in buffer 1 
Nonidet P-40, 4M NaCl, 1M (pH and 400JlI an 
protease inhibitor (Roche USA). 
were homogenised while myocytes were sonicated and then centrifuged lvV1U<',U 
at 3 000 rpm for seconds and the supernatant to a new This 
was at 5 000 for 5 to remove cellular The 
supernatant total cytosolic proteins. concentrations were 
m by the method R 1 1). all 
the total protein was resolved by sodium dodecyl sulphate­
polyacrylamide electrophoresis and were transferred to PVDF 
(Amersham Pharmacia Biotech) by electrophoretic transfer. 
specific sites were blocked by incubation in (TBS) 
20 and 5% (wt/volume) milk powder 
(Elite ), 2 hours at room Immunoblotting analyses were 
performed with the primary (Cell Signalling) and anti­
(Santa CA, USA) visualised chemiluminescent 
Relative levels were densitometric analysis 











2.4 Basal Characterisation of \Vild-type and STAT-3 KO mice 
Male (aged 1 were anaesthetised pentabarbi tone, 60 
intraperitoneal and heparinized intraperitoneal)) . an adequate 
level been was and heart 
to and KO to 
phenotypical In addition, metabolic characteristics the 
were to weight, intake and levels (Accu­
were made fortnightly and blood glucose measurement 
was taken from the tip of respective mouse's tail. 
of on the morphology 
the heart, we performed some 
KO Briefly, 14 weeks male mice were anaesthetised (as described above), 
hearts were rapidly rinsed in saline solution, . In 
Medium Germany) frozen at -80°C. 
sectioned into 1~m thick cross and processed Haemotoxylin and 
staining the laboratory of of Town.at the 
To of 













3.1 Generation of a myocardial specific STAT -3 KO mouse 
To study the functional role of STAT-3 in cardioprotection, we utilised the Cre-
Lox P technique of targeted gene excision. This strategy suited our needs, as we 
were able to obtain the mice necessary to create a unique strain of myocardial 
specific STAT-3 KO mice. Also, this technology has been shown to be effective 
in the generation of a wide variety of tissue specific STAT -3 KO mice (Jacoby et 
al. 2003; Gorogawa et al. 2004). The generation of a stable breeding colony of 
STAT-3 KO mice (as well as littermate controls) required numerous intermediate 
mouse strains, a process which took over 18 months. 
3.2 Homozygous floxed STAT-3 mice - STAT _3 F/F 
PCR analysis, of the floxed STAT -3 allele of DNA isolated from the original 
breeding mice received, showed that the mice were heterozygous for the floxed 





"' .... -_._....... 250bp 

Figure 28: peR: Floxed STAT-3 allele genotyping. peR was performed on 
DNA isolated from mice using the a+b primers for the detection of STAT-3 
floxed alleles. The 250 base pair (bp) band corresponds to the floxed STAT-3 
allele and the 200 bp band corresponds to the non-floxed STAT-3 allele. Dual 
bands are representative of STAT-3F/ N (A) and a single 250 or 200 bp band 











As our strategy required homozygous STAT-3 floxed mice, therefore these mice 
were crossbred and the offspring genotyped. The resulting litters produced 
homozygous as well as heterozygous STAT-3 floxed mice, CreNiN STAT-3 F/F and 
CreNiN STAT-3 FIN (Figure 23A). Based on the PCR results (Figure 28B) CreNiN 
STAT-3 F/F mice were selected to set up a homozygous floxed STAT-3 breeding 
colony and the CreNIN STAT-3 NIN and CreNIN STAT-3 FiN mice were discarded. 
3.3 Cre producing but still heterozygous for the floxed STAT -3 allele - CreTIN 
STAT-3FIN 
The CreTiN mice obtained are lacking the STAT-3 floxed allele; therefore it has to 
be bred into the germ line. These CreTIN STAT-3NIN mice were crossed with 
CreNIN STAT-3 F/F mice (Figure 22A). The resulting brood was genotyped for the 
Cre recombinase transgene and found to be either CreNIN or CreTIN (Figure 29). 
Offspring were also genotyped for the presence of floxed STAT-3 genes. All mice 
FINwere found to be STAT_3 in this regard. Of the genetic variations encountered, 
CreTiN STAT-3 FIN mice were selected to be crossed with STAT-3 F/F mice (Figure 
22B) to award us wi th the first myocyte specific STAT-3 KO mice. 
~""._- 350bp 
a.:::::":::fr=:. :::ai~. ~_~..--a~ 600 bp 
m c 2 
Figure 29: PCR Results: Cre genotyping. PCR analysis performed on the 
offspring of the CreTIN STAT-3N/N and CreN/N STAT-3F/ F crossing to detect the 
Cre recombinase insert. The 600 base pair (bp) band is the control PCR 
product of the wild-type MLC-2V gene and the 350 bp band is indicative of 











Myocyte specific STAT-3 KO mice and there wild-type litter mate controls 
predicted figure the 
produced first our STAT-3 KO and wild-type mice. 
These displayed numerous variations of which the 
were our first KO and 
first our wild-type It would not have been practical to generate the 
required m manner, as other were not 
required for study. shown in the square (Figure the most 
practical strategy to superIor mouse numbers would be to 
cross F/F with each other 22C). 
f,JUlj'U\A 
By the we are 
to generate both as well as wild-type Iittermate controls our 
study also to the lethal 
genotype 25A) (Chen et 1998). to this 66% of 
born are STAT-3 and born are wild- animals. 
Genetic depletion of 
mediated to remova1 of exon 21, contains 
functionally STAT-3. This in ablation 
ST AT -3 in ventricular of STAT-3 was 
biochemically with western blot presence of STAT-3 wild-type 
Ventricular was removed wild-type and 
probed are seen 










the organ specificity of our STAT-3 KO. As shown in figure 30B, STAT-3 is not 
detected in STAT-3 KO mouse ventricular tissue but still detected in the liver. 
These results serve to confirm the status of our mouse as being a cardiac specific 
STAT-3 KO mouse. 
Figure 30: Western Blot Analysis: Wild-type vs STAT-3 KO. Representative 
western blots of protein isolated from wild-type and knockout mice. Proteins 
were extracted from cardiac and liver tissue from wild-type and STAT-3 KO 
mice and the STAT-3 levels compared. 
3.6 Basal characterization of Wild-type and myocyte specific STAT-3 KO mice 
Wild-type and STAT-3 KO mice were found to be viable, fertile and visually 
indistinguishable from the wild-type mice (Figure 31). Animals were monitored 
to determine if genetic depletion of STAT-3 had any effect on basal rudimentary 
metabolism. As seen in figure 32A the comparative body weights of wt and ko 
mice were found to have no significant difference over the course of 52 weeks. 
With respect to food intake and glucose levels, statistically significant differences 













Figure 31: Photograph of wild-type and STAT-3 KO mice. No phenotypical 
distinguishing features can be observed between wild-type and STAT-3 KO 
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Figure 32: Comparative body weights, food intake and glucose levels of 
wild-type and STAT-3 KO mice. Basal characterisation of 
knockout mice. Body food intake (B) as well the blood 
(C) of and STAT-3 knockout mice was measured every 2 weeks over a 













addition, wet and KO hearts were 
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Figure 33: Comparative heart weights of wild-type and STAT-3 KO mice. 
Hearts were excised from and STAT-3 KO rinsed and blotted 
dry before being KO- knockout. 
histology analysis ....O ..,.A......... 14 weeks old not 
any in the cellular structure of 














Wild-type STAT-3 KO 
Figure 34: Cross sections of hearts from wild-type and STAT-3 KO mice, 
magnified (IOOx). No apparent difference was noticeable in the morphology 












In the section, we have described successful and breeding 
of usmg 
technology. The organ and proteomic depletion of 111 
animals was confirmed in hearts and by western blot analysis. removal 
of STAT-3 in heart did not the body weights, 
morphology of the heart, the intake and the glucose levels compared to 
litter mate controls. 
Molecular techniques now allow the of ","""viiV modifications in 
mouse (Sauer 1998). ere-Lox P technology become an important tool in the 
manipulation of the (JPn,An1 its adaptation led to development 
accurate mouse models understanding the function. 
Although much of current work exploits the alacrity and precision with which ere 
catalyses DNA recombination, ere is adept at the insertion 
DNA TPHllPUl (Sauer 1998)). 
is known as a critical transcription factor implicated in embryonic 
development mIce et 1997). The generation mice deficient in 
(whole body) by embryos degenerated 
between embryonic 7.5 probably to the of a 
functions of visceral endoderm, as nutritional insufficiency et at 
1997). this reason, we created a cardiac specific mouse to 











The organ specific nature of recombinase expression was achieved by 
the of recombinase the control of the promoter 
which is a highly cardiac and constitutively active promoter 
region (Chen et al. 1998b). Interestingly, MLC-2V has a unique function in 
contractility chamber 
during mammalian and total cardiac MLC-2V is 
lethal (Chen et al. 1998b). The ere mouse that 
we have used in our model has characterised its creator (Professor Ken 
et ai. 1 998b) successfully to 
retinoic acid rec:eD'to cardiomyocytes (Chen et 1998a). In 
the specific models, the protein was found to b 
depleted heart. 
mouse that we have in our model from has 
floxed sites into introns the exon for the 
activation residue of STAT-3 et al. 1998). These flox sites serve as 
sites for by recombinase removal of the 
DNA by crossing mice with other organ 
can 
be have for 
organ specific depletion of in pancreatic B-cells (Gorogawa et al. 
2004) and in T-cells (Takeda et al. 1998). 
To explore role of the alternative methods can be "':"·TA • ..,.".,~>" 











and of in cell culture. By allowing 
degradation of protein to continue the 
translation the protein, levels of the target nrNtp,n is depleted (Jones 
et al. 1999). technique is well suited the silencing genes in established 
cell lines et al. 2005; et ai. 2006). has been successfully 
T -cell lymphomas (Zhang et al. 2005) as well as neonatal rat 
cardiomyocytes et 2006). The recent commercial availability 
of siRNA kits Upstate UK) further the of 
In lines. 
Cre-LoxP technology, two other teams recently cardiac 
KO to explore the of heart. 2003, 
et al specific KO mouse f10xed 
flanking ex ns 18, 19 (Jacoby et al. 2003). In 
the recombinase was V"4''''vU the control the heavy 
promoter, which also tissue specific expresslOn Cre 
recombinase. As the exons they excised contained the src-2 homology 
domain (SH-2 domain) of domain is recruitment 
STAT-3 to the phoshorylation activation by J AK2), a non­
functional protein is produced. Young 
manner also not display signs of damage in line with our 
but these KO developed higher sensitivity to inflammation, heart 
dysfunction and cardiac fibrosis with advancing the of 7 months) 
(Jacobyet 2003). In 2004, et cardiac 











STAT-3 KG mouse produced by et al (Jacoby et at. 2003), mice 
were considered normal when compared to their counterparts until 9 
of age, STAT-3 mice were to display of 
failure. As we did not examine our mice at advanced ages, we can only 
speculate that our KG mouse would also develop heart 
failure as get older. No cardiac alteration was at 14 weeks old, 
that we have chosen to perform our further experiments. 
depletion of m heart was confirmed via western blot of 
proteins wild-type and 
3 KG mice 14 "r»,,"If" 12). recombinase is only expressed in the 
adult mouse heart pups born still express a functional 
However, with the progression of time, the of produced 
significantly with maximum of STAT-3 observed at 3 months 
et 2004). 
Previously, it has been reported of in the brain 
resulted m obese mice (Gao et al. 2004) due to a of leptin 
we food and body weights of 
KG and their littermate wild-type but no 
difference was observed between the two groups. depletion 
in the of the has been to impaired glucose 
secretion (Gorogawa et at. 2004). analysed blood glucose levels cardiac 
KG wild-type but no major between wild-











wild-type KO mouse hearts were measured to determine the ",",u>"", 
of depletion of on the the heart. no 
occurred between wild-type KO mouse hearts. 
fibrosis in hearts linked with an increase in the heart 
weights ofSTAT-3 KO but only with advanced (Jacoby et al. 2003). 
basal of our STAT-3 KO model, as well as literature, 
indicated that time to use our KO would be around the age 
of 14 weeks. To confirm this, histological was on 
cardiac tissue slices from wild-type and STAT-3 KO No differences were 
observed to occur under magnification of 
In conclusion, using technology, we have successfully a 
specific KO mouse. mouse will now allow us to explore the 
of In preconditioning. we will use 
14 weeks old mice as no has been noticed at this by us and other 
groups (Jacoby et at. 2003; et at. 2004). However, further 
our STAT-3 mouse (such as 
by microscopy) would be required to impact this 



























Cardiac preconditioning is a phenomenon whereby the myocardium is trained to 
resist sustained ischaemia and reperfusion injury. It can be induced with physical 
stimuli such as ischaemia or pharmacologically with agents such as adenosine 
(Aucbampach et al. 1993; Smith et al. 2002) or TNFa (Lecour et al. 2002) given 
prior to the sustained ischaemia. The damage caused during reperfusion can also 
be prevented by staged reperfusion with exogenous administration of 
pharmacological agents. The administration of insulin, at the onset of reperfusion, 
has been successfully demonstrated to prevent the damage caused during 
reperfusion (Jonassen et al. 2000; Jonassen et al. 2001). 
Ischaemic preconditioning and staged reperfusion, by exogenous administration of 
insulin, is known to protect via some common mechanisms. Akt plays a pivotal 
role in ischaemic and phannacological preconditioning (Jonassen et al. 2000; 
Jonassen et al. 2001; Krieg et al. 2002; Mocanu et al. 2002; Hausenloy et al. 
2004; Uchiyama et al. 2004) and it is activated when insulin is given at the onset 
of reperfusion (Jonassen et al. 2000; Jonassen et al. 2001). However, the exact 
protective signalling cascade still remains unclear for both protective mechanisms. 
Recent evidence supports a role for the JAK2/STAT-3 signal transduction 
pathway in protecting the myocardium from damage (Hattori et al. 2001; Negoro 











Using the cardiac specific deficient mice we are ...,.....''''....." ..F-. in our 
lao()ratofY (discussed section C), we aim to confer cardioprotection in 
mice by preconditioning or by insulin treatment at the time of reperfusion using 
two different models: 
, The isolated Langendorff perfusion model 
isolated perfusion model ischaemialreperfusion has been 
shown to be effective in studying cardiac preconditioning. This model is 
reliable and reproducible for the of signalling pathways. In 
addition, this is an established model in our laboratory. 
, The isolated adult cardiomyocytes model 
isolated and cultured adult cardiomyocytes have successfully used to 
demonstrate and investigate the powerful " ......,_"." of ischaemic preconditioning. 
culture, simulated via and use of substrate 
buffers lacking and a to 
6.2). In the STAT-3 knockout (KO) mice that we 
is depleted in cardiomyocytes only, making the use of this model appropriate 
as only cardiomyocytes are used. 
Of note, in this thesis, the ischaemic insult isolated will be termed 













2.1 Cardiomyocyte deficient mice 
STAT-3 "'~"HH~n. (STAT-3 KO) were o",.,.",,..,,,t-,,,/'1 as described in the previous 
These KO were used conjunction with littermate 
control animals all V""'IJ"'''''U All experiments were conducted accordance 
with the Guide for the Care and Use ofLaboratory Animals (Health 1996), and all 
procedures were approved by the Faculty Health Sciences Animal Ethics 
:onnrulttee, University of Cape (UCT). Animals were bred stored at the 
animal unit ofUCT until the of the experiment. 
2.2 Isolated, perfused mouse hearts 
Male mice 14-16 weeks) were anaesthetised (sodium pentabarbitone, 60 
mg/kg intraperitoneal injection) heparinized (25 IU intraperitoneal injection). 
Once an adequate of anaesthesia had been achieved, the chest was opened 
and the heart the mouse was rapidly removed, placed in cold (4°C) 
"v""",,'.va buffer and the aorta was cannulated. were then perfused a 
buffer (Sodium Chloride (NaCl) 118.0mM; Sodium 
Hydrogen Carbonate (NaHC03) 24.0mM; Potassium Chloride (KCI) 4.0mM; 
Sodium Phosphate (NaH2P04) 1.0mM; Calcium Chloride (CaCh) 
2.5mM; Magnesium Chloride (MgCh) 1.2mM; di-sodium Ethylenediaminetetra­
(EDTA) O.5mM; 10mM; 95% Oxygen (02)1 
Carbon Dioxide at °C) a retrograde fashion with a constant pressure of 
llOcm water (H20). In this modified Krebs-Henseleit buffer was added in 










1.5mM. Temperature was measured by the placement a fine thermocouple 
in the ventricle (Physitemp, NJ, USA) and monitored on a Digitron 
(Torquay, UK). were via a rigid lightweight lexan coupling rod, 
to a displacement transducer FT03C, USA) by means of a 4-0 
silk (on a 20mm curved atralurnatic needle) placed through the of 
Diastolic ten,SlO,n was adjusted to and were paced at 600 beats per 
Pacing was induced hearts as the rate is 
significantly lower than physiological rate. The was 
recorded on a chart recorder (Lectromed .........'vv ..... Letchworth, UK) 
"n,'nn""" flow rate was by collection. 
2.3 Experimental protocol: Isolated mouse heart 
the normoxic control, isolated mouse hearts were perfused for 1 00 u~••~.."'., 
normoxic Other isolated mouse hearts were subjected to 35 
minutes of global ischaemia at 37°C and 45 minutes of reperfusion (Figure 36). 
were preconditioned with a low of TNFa (0.5ng/ml), UI.!\.. llV"'Ul"" 
(100mM), administered for 7 minutes followed by a 10 minute washout period, or 
with 4 cycles of 5 minutes of global ischaemialreperfusion prior to index 
ischaemia (Figure 36). At the end of each experimental protocol, the infarct 
was by 2,3,5-triphenyltetrazoliurn chloride (TIC) Briefly, 2ml 
a 1 solution of was perfused through the followed by immersing 
heart TIC solution at 37°C for 1 minute with gentle shaking. Hearts were 
frozen at -20 and sectioned into 1.5 mm slices. These were laid out and 











enlarged, and infarct size assessed using computerised planimetry (Planimetry+, 
Boreal Software, Norway) by a researcher blinded to the groups. 
A 
He staining 















20' 10' 45'Pharmacological --~~r---~~~-------Preconditioning 
~ Pharmacological agents: TNFa (O.Sng/ml) 
Adenosine (100mM) 
~ Ischaemia 
- Normoxic perfusion 
B 
Figure 36: Langendorff perfusion of isolated mouse hearts. Hearts were 
subjected to an index ischaemia of 35 minutes followed by 45 minutes of 
reperfusion (A). Ischaemic preconditioning was conferred by 4 cycles of 5 minu tes 
of ischaemia and reperfusion prior to the index ischaemic insult. The 
pharmacological preconditioning agents were administered for 7 minutes followed 
by a 10 minute washout prior to the index ischemia. Infarct size was measured at 
the end of each protocol by TIC staining. (B) Langendorf mouse perfusion set up. 











2.4 Cardiomyocyte isolation 
Cardiomyocytes were isolated using the modified method Zhou et at (Zhou et 
at. 2000). In brief, male wild-type and STAT -3 KO mice, between 14-16 
were anesthetized as described above. Hearts were removed and perfused at 
through an aortic cannula with a calcium-free HEPES-buffered solution 
(Buffer 1, 7.4, composition: 1I6.0mM NaG, 17.4mM HEPES, 0.9mM 
NaH2P04, 5.6mM glucose, 5.4mM KCt, O.4mM Magnesium Sulphate (MgS04). 
Cannulated hearts were perfused with Buffer 1 containing 0.025mM EGT A and 
0.1 % for 10 minutes to remove all blood (Figure 37). 
Restoration 
buffer 
10' 15'-25' 10' 
Buffer 1 + Buffer 1 +Buffer 1 + 
EGTA+BSA 

Figure 37: Cardiomyocyte extraction protocol. Isolated and cannulated 
hearts were perfused in a step wise manner. First, they were perfused with 
Buffer 1+ EGTA+BSA to remove the blood. Then collagenase was used to 
digest the heart tissue. Finally the collagenase was washed out in Buffer 1 + 
before hearts were transferred to a restoration buffer. CaCh- calcium 
EGTA- ethidium glycine tetra-acetic acid. 
Hearts were then perfused with Buffer I containing collagenase type II 
(OJ4mg.mr 1) (Worthington Biochemicals) and (25J.!M), in a recirculating 
manner for 15 - minutes to digest the hearts. collagenase was washed out 
from digested hearts with Buffer I with 25 j.lM CaCh for 10 minutes, before 
being removed from the cannula and minced finely with scissors in 











carnitine, 5.0rnM taurine, 5.0rnM ,.,...""(1n ..... and O.lrnM and 1% BSA, pH 
7.4) (Figure 37). minced tissue suspension was .;tH"'''',",U vigorously at 37°C for 
15 minutes, resulting suspension was filtered through a sterile nylon mesh 
(40llm mesh size, Spectrum Laboratories Inc.) and cells pelleted 1500rpm 
10 minutes, Sanyo Harrier 18/80). supernatant was decanted and the 
resuspended in 25m! buffer. 100rnM calcium was added in an 
incremental manner to achieve a final concentration of 1.2SrnM over a period of 
12 minutes. Cells were spun down at 1500rpm for 10 minutes and resulting 
pellet cardiomyocytes was resuspended in modified, insulin free, 
(Kawamoto, Sato, McClure, and Sato) (Kawamoto et al. 1986) media. Isolated 
cardiomyocytes were quantified and a threshold 60% viable rod shaped 
myocytes was considered to be a quality preparation of isolated 
cardiomyocytes. Isolated myocytes were in standard tissue culture 
for 1 at 37°C a humidified 5% C0:2 atmosphere prior to eXI)enlm~mtllt1 
2.5 Experimental protocol: Isolated cardiomyocytes 
Isolated cardiomyocytes were exposed to simulated ischemia (SI) in a modified 
Esumi Buffer (Esumi et al. 1991) containing: 118.0rnM NaCl, 3.6rnM KCl, 
O.SrnM MgCh, 0.9rnM 4.0rnM and 20.0rnM 2-deoxy-D-gJucose 
(2-DG) at pH for hours, at 37°C, a humidified environment containing 
1% 02, C02 and N2• was followed by 2 hours of 
reoxygenation in insulin KLSMS media (Figure 38) under nonnoxic 











pH 7.4, a humidified environment 20% 5% CO2 and balance N2 
28 hours 38). Myocytes were preconditioned by exposing cells to 
1% in Esumi without 2-DG at pH 6.4 for minutes. This was followed 
by 60 reoxygenation under conditions in KSLMS, hours of 
ischaemia, in Esumi without and 2 
reoxygenation in media (Figure 38). Cardiomyocytes were 
pharmacologically preconditioned by adding 0.5nglml TNFa or 100mM 
adenosine to KSLMS for 30 under conditio s followed 
by a 60 washout period to 26 hours simulated ischaemia and 2 












Reoxygenation +--- Insulin -+ 
Hypoxic and Pharmacological preconditioning period 
Pharmacological agents: TNFa (O.Sng/ml) 
Adenosine (100mM) 
~ Simulated Ischaemia 
Normoxic Conditions 
Figure 38: Experimental protocol in the isolated cardiomyocytes. The index 

simulated ischaemia lasted for 26 hours and the fmal reoxygenation time was 2 

hours. Cells were preconditioned for 30 minutes with hypoxia, TNFa or 

adenosine followed by one hour washout period prior to the index ischaemia. 














2.6 Measurement of viability 
Cardiomyocyte viability was measured at the end of the 2 hour reoxygenation 
period trypan blue exclusion as well as morphology (Zhou et al. 2000; 
Marais et al. 2001) by a researcher blinded to the groups. Results are ,",,,,,,,,,",,,,,,",,rI as 
percentage (%) ofviable myocytes. 
2.7 Pharmacological 
Collagenase, was purchased from Worthington Biochemicals (New Jersey, 
USA). Insulin free KSLMS medium was obtained from Highveld Biologicals 
(Johannesburg, South Africa). Recombinant murine TNFa was obtained from 
Peprotech Inc (Rocky Hills, NY). Actrapid (ge) insulin (Novo Nordisk) was 
purchased at the local pharmacy. All other including adenosine were 
obtained from Sigma Biochemicals (St. Mo, USA). 
2.8 Statistical Analysis 
Results are ,",,,t".,.,,,,,,,,,,,,rI as mean ± standard error of the mean (S.E.M.) 
were analyzed by one-way ANOV A Dunn's post-test, using InStat 
3.01 (Graphpad software, San '-" ....""v. California, Differences were 












The Role of STAT-3 in Ischaemic Preconditioning 
evaluate the physiological significance STAT-3 in ischaemic 
preconditioning we used the isolated perfused heart model 
ischaemiaireperfusion injury as well as isolated cardiomyocytes. 
a) Isolated mouse heart 
Following an ischaemiaireperfusion insult, the infarct (expressed as a 
percentage the whole heart) was similar between wild-type KO 
mice (wild-type; 35.8±1 and KO; 38.4±2.6%; ns) (Figure 
Ischaemic preconditioning reduced the size in wild-type mice to 
(p<O.05 vs ischaemic control; but not the KO (43 
ns vs ischaemic ~6) (Figure 
c:.J Wild-type 
50 











IN.......·.,. 39: Effect of ischaemic preconditioning (IPC) in isolated wild-type and 
STAT-3 KO mouse heart. Hearts were to 30 minutes of global index 
ischemia and 45 minutes of (Ischaemic control). Hearts were 
preconditioned with four cycles of 5 minutes of ischemia and 5 minutes of 
(IPe) to the index ischemia. and STAT-3 KO hearts were 
found to have similar infarct sizes in the ischaemic control Wild-type hearts 
preconditioned prior to the index ischemia had infarcts than 
those of control hearts. STAT-3 KO mice could not be IPC. *p<0.05 vs 










b) Isolated Cardiomyocytes 
Similar results were obtained using isolated cardiomyocytes 40). 
isolated cardiomyocytes to index simulated ischaemia resulted in a similar 
of myocyte viability in wild-type and STAT -3 KO (wild-type 
and KO 100% myocyte viability to 1% and 58.6±3.5% 
respectively; n~6). Preconditioning the cardiomyocytes with hypoxia improved 
viability in wild-type (88.5±3 *p<O.OOl vs 
had no protective myocytes of KO animals vs 

















.. STAT-3 KO 
Normoxic Simulated HPC 
Control Ischaemia 
40: Effect of hypoxic preconditioning (HPC) in isolated wild-type and 
STAT-3 KO mouse cardiomyocytes. were isolated from intact wild-
type and STAT-3 KO hearts and were 
ischaemia and 2 hours of 
preconditioned with one 
to either 26 hours of simulated 
and 1 hour "'''''.V>''YP 
the simulated ischaemia (HPC) Simulated ischaemia decreased 
IT",r."UTP cell viability in both 
cell viability of but not of 
< 0.01 vs simulated ischaemic. n2:6. HPC-












The Role of in Pharmacological Preconditioning 
in pharmacological preconditioning, we used 
TNFa as preconditioning mimetics. 
a) Isolated mouse heart 
Adenosine TNFa reduced the infarct compared to ischaemic 
(l7.2±3.l 24.6±2.5% reSI)eCltlVe p<O.O 1 vs ischaemic control; 
(Figure 41). contrast, preconditioning mimetics to precondition the 
KO against sustained ischaemia I.O±2.9% 41 1% 


















Figure 41: Effect of pharmacological with adenosine or 
TNFa, in isolated wild-type and STAT-3 KO mouse heart. Wild-type mice were 
against injury with either lOOmM 
adenosine or O.Sngjml TNFo. Both decreased the infarct size when 
to the ischaemic control in wild-type mice. In contrast, neither 
influence on the STAT-3 KO hearts. 1 
vs ischaemic control. nc=S. 
96 










b) Isolated Cardiomyocytes 
Similar results were obtained In isolated cardiomyocytes model. 
adenosine TNFa improved cardiomyocytes viability in wild-type hearts 
(83.0±2.6% and .O±3.8% respectively; p<O.Ol vs ischaemic 
(Figure 42). However, these agents failed to protect the 
cardiomyocytes (54.6±1.3% 1±4.0% respectively; ns; (Figure 42). 
o Wild-type 









Simulated TNFa Adenosine 
Ischaemic (O.5ng/ml) (100mM) 
Figure 42: Effect of pharmacological preconditioning, with adenosine or 
TNFa, in isolated wild-type and STAT-3 KO mouse cardiomyocytes. 
were PC with a 30' of exposure of either adenosine (lOOmM) or TNFa (0.5ng/ml). 
Both PC mimetics improved cell viability in myocytes but failed to 













Reperfusion injury can be reduced at the onset 
of reperfusion. O.3mU,3mU 30mU of insulin I viability in 
wild-type (8S.2±3.4%, 81 and 96.2±S.7%; p<O.OOl vs 
ischaemic n>6) (Figure However, improvement m 
cardiomyocytes viability was not cells from 



















Simulated Insulin Insulin Insulin 
Ischaemic (O.3mU/ml) (3mU/ml) (30mU/ml) 
Figure 43: Effect of with insulin at the time of in isolated 
wild-type and STAT-3 KO mouse cardiomyocytes. Insulin improved the 
myocyte survival rate in wild-type but had no effect on myocytes 












The finding this study is genetic of m 
cardiomyocytes abolishes capacity to activate ischaemic 
preconditioning. addition, pharmacological preconditioning adenosine or 
the cytokine was unable to <ll'riu<I't" this cardioprotective 
the isolated perfused mouse and cardiomyocytes. Furthermore, 
deleterious of 1""..'''1"1,..''''.'''.., induced injury was not .....''''....... by staged 
rer;,erJilsllon with insulin isolated KO cardiomyocytes. Taken together, 
these data that signalling is required 
cardioprotection. 
activation STAT-3, in reSDOltlSe to stress, has reported as an 
important event pro-survival signalling (Hattori et al. 2001). STAT-3 is 
activated by the receptor bound tyrosine JAK2 an sCfllaerruc or 
oxidative stress (Negoro et al. 2001). This pathway is an important 
part signalling cascade from the membrane to nucleus in which rVn)SUle 
phosphorylation of leads to dimeristaion monomeric 
(Mascareno et al. 2001), translocation to the and the to promoter 
'"'F,.'U'.." of DNA and expression (Ible 1996). 
inability to activate cardioprotective program by ischaemic 
pharmacological preconditioning as well as staged reperfusion with insulin in 
these deficient cardiomyocytes, raises several interesting 











other signalling pathways or interacting with signalling on;~aflieW~s v'...."' •• " ... " 
nucleus. interaction of transduction pathways is 
although there is an of STAT and MAPK 
signalling (Ihle 1996) and Akt (Gross et al. 2006). 
Recently, et al have suggested that PI3K mediated Akt activation, in 
opioid-induced preconditioning, is mediated by (Gross et al. 2006). 
The obligatory role Akt in both and pharmacological preconditioning 
as well as reperfusion is well documented (see by 
(Hausenloy el al. 2004». The seclond possible function is that may 
as a distal final common mediator ofpn;~condl.tlOmI1lg-lneli11 cell survival 
However, this possibility is unlikely as pharmacological of 
downstream cardioprotective mediator GSK3~ still 
cardioprotection et al. 2006). The third possibility is that cardiomyocytes 
functional are deficient in one or more regulated 
proteins which may play obligatory role in cardioprotection. In brief, STAT-3 has 
been shown to involved in regulation carbohydrate metabolism (Inoue et 
al. 2004) and lack of functional STAT-3 may lead to perturbations in 
metabolism within cells that the metabolic adaptations associated 
with preconditioning (Opie et al. 2002). Moreover, proteins 
involved regulating apoptosis Bc1-2 and (Hattori et al. 2001). 
Here, lack of may alter the balance of anti-apoptotic versus pro-apoptotic 
within cardiomyocytes. Finally, STAT-3 signalling modulates the 
regulation of the antioxidant defence system via the upregulation of manganese 













"''''.1.'''''''''''', abolishes the pre:cOllOlt.l()n........ program (Das et al. 2003). Furthermore, 
cardioprotection observed mice attributed to 
up regulation of the anti-oxidants metal1otnlIonnen 1 and 2 (Oshima et al. 2005). 
As to act in a part, transcriptional regulatory 
control, it is intriguing that the depletion of protein can 
nullify the classical preconditioning nrr\crr,>IrY1 that is thought to be predominantly 
orchestrated post-translational events. It is interesting to note that mUltiple 
other organs can be preconditioned including (Hardy et al. 1996), kidney 
(Islam et al. 1997) and brain (Gidday et al. 1994). Other cell that are ....."'''''''.. 
the intact heart including epithelial cells (Minners et 2001), endothelial 
(Andjelkovic et 2003), et al. 2002) and 
fibroblasts (Han et al. 2001) capacity to preconditioned. 
as cardiomyocytes represent about 30% of cell number 
approximately 75% of volume (Erikson et al. 1996), and as preconditioning 
triggers applied to remote organs can also precondition the heart (Verdouw et al. 
1996), we determined the extra cardiomyocyte components of the heart could 
rescue the preconditioning phenotype the intact isolated mouse heart. 
The inability to protect the myocardium in presence types found 
heart ................"'.,..... that STAT-3 the cardiomyocytes is to induce 
protective phenotype on the heart. 
To conclude, using functional genomic depletion studies, we have shown that 














injury in cardiomyocytes. Furthermore, the loss of in cardiomyocytes 
cannot cornpe:nsl:1tted for by non-cardiomyocyte cellular components the 
intact heart. 
The challenge of using data solely from KO animals is that genetic depletion of 
STAT-3 may cardiac "'......'..,..........., or function the heart, which are not 
related to preconditioning. 'helret()re. to our data and explore the 
role of as an intracellular signalling protein we used pharmacological 
agents to inhibit STAT-3 activation and confirm the loss of cardioprotection 
observed is specifically due to ._...,".!'>' In addition, 
STAT-3 exerts a protective ~~A'''.!'> the trigger and not the 























hence ...." ... 'V'LL"' .. the 
1. 	Introduction 
In the previous section, we shown that cardiac specific STAT-3 KO 
to be ",..",t",,,,+,,,rI from ischaemiafreperfusion 

importance of 
 activation in both ischaemic pharmacological 
preconditioning. However, challenge of data from animals is 
depletion ofSTAT-3 may cardiac development or functions which 
are not related to cardiac preconditioning. Furthermore, this data does 
not identify at which time point (during the preconditioning stimulus or at the 
of reperfusion) activation is required for cardioprotection to occur. 
Therefore, chapter: 
Using a specific pharmacological inhibitor of the JAKISTAT-3 pathway, we 
hypothesized that activation of STAT-3 during the preconditioning stimulus 
(ischaemia, hypoxia or TNFa) is required for preconditioning to confer 
cardioprotection. In addition, we aim to delineate a possible cross-talk 
between the JAK2/STAT-3 pathway and already described PI3K1Akt 











PC Stimulus: TNF, ischaemia or hypoxia 
JAK2
PI3K 
? ~ ~ • 
Akt "illOIII----fJlo-1I> STAT-3 
Cardioprotection 
14"••" ....... 44: Hypothesis: The role of STAT-3 and Akt as stimuli 
in ischaemia- and TNF-induced preconditioning. JAK2- janus kinase 2, mTOR­
mammalian STAT-3­
transducer and activator of 
of rapamycin, PI3K­
Inhibition of pathway is achieved with the tyrphostin AG490 
(Figure 45). Previous findings have shown the pharmacological inhibition with 
AG490 abolishes the acute protection seen in ischaemic preconditioning as well as 
significantly depresses phosphorylation levels in isolated rat heart 
when prior to an " ...<l':a...,....'" preconditioning (Hattori et al. 2001). 
AG490 binds to JAK2 hence, ore:vel[UlrUl the binding and subsequent activation 
STAT-3 (Figure 45). Inhibition of the PI3 KI Akt pathway is achieved with either 
wortmannin or rapamycin (Figure 45) (Jonassen et al. 2001). The actions of both 
inhibitors are well documented in their abilities to inhibit signalling pathway. 
Wortmannin ......"''''''...1'''' the phosphorylation of PI3K mediated phosphorylation and 











the signaling pathway by inhibiting mammalian target rapamycin 







Figure 45: 	AG 490 mediated inhibition of the signaling 
pathway. 	Signal transduction the JAK2jSTAT3 can be 
inhibited with AG490 which nre""""n1"o JAK2 mediated activation STAT-3. 
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Figure 46: Wortmannin and rapamycin mediated inhibition of the 
PI3KIAkt signaling pathway. Signal transduction through the PI3KjAkt 
pathway can be inhibited with wortmannin which prevents PI3K mediated 
activation of Akt or with which blocks mTOR, a downstream 













2.1 Isolated mouse cardiomyocytes 
The protocol used to ,...,"'" ..."" cardiomyocytes is described in section D 2.4. Isolated 
myocytes were exposed to simulated ischaemia/reperfusion injury and 
preconditioning ......",t",,,·,,, described in section 2.5 (Figure 38). Pharmacological 
inhibition of the PBKJ Akt pathway was achieved with, wortmannin (1 00mM) or 
.."'.... '''' ...... '"..'" (0.5nM) and STAT-3 activation was inhibited with AG490 OOmM). 
AU these inhibitors were given during the preconditioning stimulus with a 
washout "'''''''''''1"'1 of one prior to the simulated ischaemia 47). 
concentrations of wortmann in and rapamycin used have been successfully 
demonstrated to inhibit the PBKJ Akt signaling pathway in both cells and the 
!;:)VU:U,",U rat (Jonassen et al. 200 The used STAT-3 
corresponds to the of the which has demonstrated to inhibit the 
phosphorylation levels of STAT-3 in cell culture models (Dowlati et al. 2004). 
Cardiomyocyte viability was at the end of 2 hour reoxygenation 
period trypan blue exclusion as well as cell morphology (Zhou et al. 2000; 
Marais et al. 2001) by a researcher .... LA'"'''',",''''' to the Results are expressed as 















Control 28 hrs 1 
Simulated 
Ischaemic 26 hrs 
Control 
Pharmacological 30' 26 hrs 
and Hypoxic 
Preconditioning 
- Normoxic Conditions ffiill] Hypoxic and Pharmacological preconditioning period 
Pharmacological agents: TNFa (0.5ng/ml) 
....... Inhibitors: AG 490: 100mM 
Wortmann!n: 100mM ~ Simulated Ischaemia 
Rapamycln: O.5nM 
47: Tissue culture protocols of isolated cardiomyocytes. Cells were 
exposed to a 26 hours simulated followed 2 hours of re()X)'genanon 
Cells were with 30 minutes hypoxia or TNFa (O.Sngjml) followed 
by a 1 hour washout period prior to the simulated ischaemia. cell 
viability was measured at the end of each protocol via trypan blue exclusion. 
The inhibitors AG490, rapamycin or wortmannin were added to the buffer 
DT~:CUl[lal ..v',HuF. stimulus. IPC- Ischaemic i:"'re~co:nQl"LU,uu5' 
2.2 Isolated perfused rat hearts 
Male '-''-',.... ...., rats (250 to were anesthetised (sodium pentobarbitone 
60mglkg; intraperitoneal) heparinised (200IU intraperitoneal). were 
excised rapidly retrogradely by the technique at a 
constant pressure (100crn H20) with oxygenated Henseleit buffer 
(llS.OmM NaCI, 25.0mM NaHC03, 11.0mM Glucose, 4.7mM KCl, 1.2mM 













the left the left and the left end diastolic 
was adjusted h""~'Il""'>" 4 and AU hearts were subjected to 30 
minutes of regional ischaemia by occlusion of the left coronary artery followed 
minutes of ,.",....",,.1h. (Figure 48). were preconditioned either a 
low dose of TNFa that was followed a 10 
washout before standard "'V.,,"''''~~H''' or with 2 cycles of S of 
ischaemic/reperfusion prior to standard ischaemia (Figure 48). AG490 
OOmM), UT"..,'...... (100mM) rapamycin (O.SnM) were given concurrently 
the preconditioning triggers .<4"'l"l" and TNFa 48). For SIze 
measurements, the coronary artery was re-occluded at end of the .."...",yn 
period, and a of 2.5% blue was perfused to delineate area at 
Hearts were frozen n"'~'rnl and into 5 equal sections the 
following day. infarcted area was stained with a 1 TTC solution at for 
minutes. sections were then scanned, enlarged, and infarct size was 
assessed computerised t"~"''''~'' (planimetry+, Boreal Software, Norway) 
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PC ... 
- Normoxlc perfusion W,] TNFa 
... Inhibitors: AG 490 (IOOmM) ~ Ischaemia 
Wortmannin (lOOmM) 
Figure 48: Rat heart Langendorff perfusion protocols. Rats were subjected, to 
an index ischaemia of 30 minutes and the final reperfusion time was 120 
minutes. Ischaemic preconditioning was conferred by 2 cycles 5 minutes of 
ischaemia and reperfusion prior to the index ischaemic insult. TNFa was 
administered for 7 minutes followed by a 10 minute washout period prior to the 
index ischemia. The inhibitors AG490, rapamycin and wortmannin were infused 
during the IPC or TNFa administration period. Infarct size was measured at the 
end of each protocol via TIC staining. IPC- Ischaemic Preconditioning, PC­
Preconditioning. 
2.3 Western blot analysis 
Control isolated myocytes were cultured in KSLMS media for 16-24 hours, spun 
down at 1500 rpm for 10 minutes and resuspended in ice-cold PBS before being 
pelleted, by spinning the cells down at 1500rpm for 10 minutes, and stored at ­














or TNFa-induced preconditioning protocols they were 
collected after 15 minutes or ......... ,,"'.., of treatment in the same conditions than 
the control group. Cytosolic proteins were extracted as described previously 
section C 
2.4 Pharmacological agents and anti-bodies 
Recombinant murine TNFa was obtained from Peprotech Inc Hills, NY). 
Anti-bodies for phospho-Akt, phospho-STAT-3 and total Akt were obtained from 
Cell 'hA',.... ,,'u.... and anti-bodies for total ~-Actin and all secondary anti­
bodies were obtained from Cruz (Santa Biotech, All 
were obtained from Sigma Biochemicals (S1. Louis, Mo, USA). 
Statistical analysis 
~~~,., ......, are expressed as mean values ± standard error the mean and 
were analyzed by one-way ANDV A with Dunn's post-test, GrapbPad InStat 
3.01 (Graphpad software, 	 Diego, USA). Differences were 














3.1 Inhibition of STAT -3 activation during preconditioning abrogates the 
protection due to ischaemic- and TNFa-induced cardioprotection 
To investigate the role of STAT-3 during ischaemia- (isolated rat heart), hypoxia­
(isolated mouse cardiomyocytes) and TNFa-induced (both models) 
preconditioning we administered AG490, the STAT-3 inhibitor, during the 
hypoxic or TNFa preconditioning phase. As previously reported in section C, 
myocytes cell viability following a simulated ischaemialreperfusion insult was 
55.9±1.9% (Figure 49). Both hypoxia­ and TNFa-induced preconditioning 
improved myocytes viability to 88.5±3.6% and 83.0±3.6% respectively 
(***p<O.OOI vs simulated ischaemia for both preconditioning stimuli; n2:6) 
(Figure 49). Administration of AG490 inhibited the cardioprotective effects of 
both hypoxic and TNFa-induced preconditioning in isolated cardiomyocytes 
(myocyte viability in hypoxia-induced preconditioning+AG490: 62.9±2.8% and 
























Figure 49: The role of STAT-3 in hypoxia- and TNFa-induced 
preconditioning using an isolated mouse myocytes model. Inhibition of 
STAT-3 with AG490 given during the hypoxia or TNFa preconditioning period. 
abrogates the protection due to both preconditioning stimuli. ***p<O.OO 1 vs 












Similar results were obtained in the isolated rat heart. Both ischaemic 
preconditioning and TNFa. administration reduced the infarct size compared to the 
control group and this protective effects were lost in the presence of AG 490 
(Infarct sizes for Control: 32.7±3.0%, ischaemic preconditioning: 6.5±2.2%, 
ischaemic preconditioning+AG490: 29.6±5.0%, TNFa.: 9.4±2.9% and 
TNFa.+AG490: 41.64±4.6%, n2:6) (Figure 50). Of note, AG490 on its own did not 
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Figure 50: The role of STAT-3 in ischaemia- and TNFa-induced 

preconditioning in the isolated rat heart model. Inhibition of STAT-3 

with AG490 given during the trigger phase abrogates the protection due to 

Ischaemic and TNFa-induced PC. ***p< 0.001 vs Control. n~6 per group. 

IPC- Ischaemic Preconditioning. 

Western blot analysis ofSTAT-3 phosphorylation showed an increase in STAT-3 
activation during TNFa. administration (Figure 51 A: expressed in Arbitrary Units 
(AU) from 174.3±35.6 for the control to 514.3±10.7 after 30 minutes of TNFa 
exposure; ***p<O.OOI vs control; 1126) as well as during a hypoxic 
preconditioning stimulus (Figure 52A: in AU from 102.l±16.7 for the control to 
180.5±5.1). Administration of AG490 during both preconditioning stimuli 
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Figure 51: STAT-3 activation in cardiomyocytes exposed to TNFa.. 
Densities expressed in Arbitrary Units (AU) showed that STAT-3 
phosphorylation was increased during TNFa (O.Sngjml) exposure (A). This 
increase was lost in the presence of AG 490 (B). *p<O.OS vs control, **p<O.O 1 
vs 30' TNFa.. n~4. 
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Figure 52: STAT-3 activation during a hypoxia. Densities expressed in AU 
show that STAT-3 phosphorylation was increased during a hypoxic 
preconditioning stimulus (A). This increase was lost in the presence of AG 















3.2 Inhibition 	of Akt activation during the preconditioning phase abrogates the 
protection due to ischaemic- but not TNFa-induced cardioprotection 
To study the role of the PI3K1Akt pathway in ischaemic and TNFa-induced 
preconditioning, we determined myocytes viability following inhibition of the 
PI3K1Akt signaling pathway during the preconditioning stimulus (wortmannin 
was used to inhibit PI3K and rapamycin was used to inhibit mTOR kinase). Both 
wortmannin and rapamycin, given during the hypoxic preconditioning stimulus, 
abolished the protective effect afforded by preconditioning (myocytes viability 
55.2±4.0% and 53.2±4.1 % respectively, ns vs simulated ischaemia; n>6) (Figure 
53). In contrast, these inhibitors failed to reverse the protection afforded by TNFa 
(85.0±5.9% and 93.4±2.3% respectively, ***p<O.OOlvs simulated ischaemia, n2:6) 
(Figure 53). 
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Figure 53: The role of Akt in hypoxia- and TNFa-induced preconditioning 
using the isolated mouse myocytes model. Inhibiting the activation of 
PI3K/Akt pathway with mammalian Target of Rapamycin (mTOR) with 
rapamycin (R) or wortmannin (W) given during the trigger phase prevented the 
protection due to HPC in isolated cardiac myocytes. In contrast, TNFa-induced 
protection was not abrogated in the presence of these inhibitors. ***p<O.OO 1 vs 













Similar results were observed in the isolated rat heart with ischaemic and TNFa 
preconditioning. Here, wortmannin inhibited the protective effect of hypoxic 
preconditioning but not ofTNFa (Control-32.7±3.0%; Ischaemic Preconditioning­
6.5±2.2%; Ischaemic Preconditioning+W-16.9±3.5%; TNFa-9.4±2.9; TNF+W­
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Figure 54: The role of Akt in ischaemia- and TNFa-induced 
preconditioning using the isolated rat heart model. Inhibition of Akt 
activation during the trigger phase abrogates the protection due to ischaemic 
but not TNFu-mediated cardioprotection. ***p< 0.001vs control. n~6. IPC­
ischaemic preconditioning, W- wortmannin. 
3.3 Hypoxia but not TNFa triggers Akt activation 
To confirm the role of Akt during the trigger phase, we examined the 
phosphorylation of Akt during the hypoxic and TNFa preconditioning stimulus in 












following 15 minutes and 30 minutes of hypoxia (in AU from 100 in the control to 
158.4±3.1 and 192.2±7.3 
respectively; p<O.OOI vs 





15 minutes and 30 
~6) (Figure 55A). 
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at both time points 
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Figure 55: Akt activation during a hypoxic or a TNFa preconditioning 
stimulus. Densities expressed in Arbitrary Units (AU) showed that a HPC 
stimulus (A) and not a TNFa (O.Sngjml) stimulus (B) increased Akt 
phosphorylation Akt. ***p<O.OOl vs control. n~4 per group. Abbreviations are as 
defined in text. 
3.4 Cross-talk between Akt and STAT-3 
To determine whether a cross-talk between Akt and STAT-3 activation may exist, 
we determined STAT-3 phosphorylation in the presence of the PI3K1Akt inhibitor 
(wortmannin) and the phosphorylation of Akt in the presence on the JAK2/STAT­












specific STAT-3 KO mice following a hypoxic preconditioning stimulus. Western 
blot analysis of STAT-3 phosphorylation showed that wortmannin decreased 
STAT-3 activation during a hypoxic preconditioning stimulus (265±45 AU for 30' 
of hypoxia and 120±28 AU for 30' of hypoxia + wortmannin, p<0.05 vs 
30'hypoxia; ~6) (Figure 56). Addition of AG490 during the hypoxic 
preconditioning stimulus prevented Akt phosphorylation. (156± 19.8 AU 
following a 30 minute hypoxic stimulus to 64.l±12.3 AU, p<O.Ol vs 30' hypoxia) 
(Figure 57). Similarly, genetic depletion of cardiac STAT-3 prevented Akt 
phosphorylation following 30 minutes of a hypoxic preconditioning stimulus (set 
to 100 AU in the control to 101±5.6 AU following 30' hypoxia. ns, n~4) (Figure 
58). 
P-STAT-3 -+ 






















Figure 56: STAT-3 inhibition with wortmannin during hypoxia. Densities 
expressed in AU show that wortmannin prevents an increase in STAT-3 









































phospholation during hypoxia. 
Densities expressed in arbitrary units (AU) showed that AG490 prevents an 
increase in Akt phosphorylation following an hypoxic insult. ***p<O.OO 1 vs 30' 
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Figure 58: Akt phosphorylation in STAT-3 KO mice during hypoxia. 
Densities expressed in arbitrary units (AU) showed that genetic ablation of 













Using different models and animal species, the novel data in this study 
for first that pharmacological preconditioning with the cytokine 
requires phosphorylation The 
protection observed occurs independently of the Akt activation suggesting parallel 
protective cascades. Furthermore, we confirm previous findings 
a protective role for both Akt STAT-3 as triggers of ischaemic 
preconditioning. In addition, we demonstrate possibility a cross-talk 
Akt and STAT-3 activation in preconditioning. 
During .",." ..,.,.,...... (Schulz et al. 2004), in heart failure (Aker et al. 2003) or 
following microembolization (Thielmann et al. 2002), myocardial and/or 
serum TNFa is increased and causally involved in contractile dysfunction. In 
contrast, in vitro experiments conducted rats or mice hearts have shown that 
could cardioprotection an 
ischemiaireperfusion insult in a time- and dose- dependent manner (Lecour et al. 
Smith et al. 2002). However, these in vitro models represent limitations in 
that they do not into account the intracoronary activation of leukocytes which 
may an opposite effect of in the setting of myocardial 
have previously confirmed that TNFa could mimic ischemic preconditioning 
in vivo to a similar extent as in isolated rat model (Lecour et al. 2005b). 
Interestingly, the protective dose of TNFa (0.1 used in vivo is within 
1) of the used to mimic preconditioning in isolated rat 
heart (O.Snglml) and 2) of amount of TNFa endogenously In 











concept of mUltiple pathways in preconditioning already suggested 
.. 

In to the phase (Yell on et 2003). Using an isolated rat heart 
model with global ischemiaJreperfusion, we found sphingolipids are involved 
with TNFa.-induced preconditioning but not with ischemic 
preconditioning et al. 2002). contrast, activation of tyrosine kinase is 
required in preconditioning (Vahlhaus et al. 1998; Fryer et al. 1999) 
not necessarily In pharmacological preconditioning et al. 2004). We 
investigated the the JAK2/STAT-3 pathway as the possible 
.... 01'1'\"'0" which in TNFa-induced preconditioning. The role 
has previously been reported the phase in ischaemic 
preconditioning (Bolli e/ al. 2001; Hattori et 2001) not in 
preconditioning. Using two models of cardiac ischaemiaJreperfusion, we were 
able to abolish cardioprotective effect assocllate:d with ischaemic or TNFa.­
induced preconditioning the inhibitor AG490 was during 
preconditioning stimulus. Furthermore, protection observed with both 
preconditioning stimuli was associated with phosphorylation STAT-3 during 
and after preconditioning stimuli. TNFa transmits a signal two distinct 
TNFRI and TNFR2 which both intrinsic activity in their 
intracellular domains et al. 1998). Due to this, they via interactions 
with signaling kinases, such as JAK2, which is to be constitutively 
associated with intracellular domain of receptors. STAT -3 is activated 












The signaling cascade associated with the activation STAT-3 following a 
preconditioning stimulus still remains to be elucidated. We have previously 
reported that TNFa-induced cardioprotection is dependent of ROS (Lecour et al. 
2005a) and recent by Sauer et al (Sauer et al. 2004) demonstrated that 
treatment of cardiomyocytes with cardiotrophin-l (also a cardioprotective 
cytokine) stimulated STAT-3 phosphorylation in a ROS manner. 
experiments will be required to explore whether a cross-talk may exist 
betweenROS and STAT-3. 
During the preconditioning stimulus, it is now well established that activation of 
Akt is require to confer cardioprotection (Mocanu et al. 2002). addition, many 
pharmacological agents such as adenosine (Auchampach et al. 1993), opioids 
(Cohen et al. 2001; Gross et al. 2006), bradykinin (Cohen et 2001) all protect 
via activation of Akt the trigger phase. Our data show for the time 
that a pharmacological preconditioning compound can protect independently of 
the activation of Akt the trigger phase. data supports the concept of 
multiple signaling pathways in preconditioning. 
As STAT-3 and Akt activation are required ischaemic preconditioning, we 
aimed to explore possible cross-talk between two intermediates the 
protective signaling we showed that inhibition Akt with 
wortmannin inhibited phosphorylation thus ug1.!~estmg that 
activation may occur downstream of Akt activation. contrast, inhibition of 
with AG490 also inhibited Akt phosphorylation thus suggesting that 













phosphorylation of Akt did not occur in cardiac specific KO 
exposed to an ischaemic preconditioning stimulus. all together, 
results andsuggest presence a m 
ischaemic preconditioning. In 1997, at al. demonstrated that the 
regulatory subunit PI3K can promote serine phosphorylation of 
which is for formation homodimers (Pfeffer et al. 
In pulmonary artery endothelial activation with carbon 
monoxide exposure is dependent on PI3K1Akt pathway (Zhang et 2005). 
2001, it was demonstrated that JAK2 can phosphorylate Akt after binding to the 
u .... '-,u'"'"" p85 PI3K (Nguyen et al. 2001). More Gross et aI, used an 
in vivo rat model of ischaemia-reperfusion a cell culture (H9C2 
cardiomyoblasts) to show that opioids induced cardioprotection via the activation 
JAK/STAT-3 PI3K1Akt pathways and that phosphorylation was 
dependent on PI3K activation et al. 2006). They ~F>E",V"" that the observed 
protection is due to JAK2 regulated, dependent phosphorylation of 
Akt GSK3~, with GSK3~ playing a role in cardioprotection. Further 
experiments into the of GSK3~ in TNFa.-induced preconditioning will be 
required to determine whether GSK3~ plays a role TNFa.-induced 
preconditioning. is in concordance with our data STAT-3 knockout 
mice, in contrast to their littermate control failed to increase phosphorylation 
following an ischaemic preconditioning insult. together these results 
provide an answer to puzzling role of which is a transcription factor, 
classical pn~conam(mu which predominantly, occurs via post-translational 












In summary, TNFa-induced preconditioning the activation of 
during preconditioning stimulus but occurs independently PI3KJAkt 
signaling. In contrast, ischaemia-induced occurs via dual 
activation of both the PI3KJAkt JAK2/STAT-3 signaling pathways with the 
recruitment of STAT-3 to the receptor by JAK2 forming part a signaling 











F. The Role of STAT -3 and Akt as mediators of cardiac 
preconditioning 




NB: Part ofthe langendorffperfusions and western blot analysis presented in this 












interest surrounding cardiac preconditioning is centered on the events that 
occur at the onset 	of reperfusion. no investigation place to 
of the ""/S,lU4JlHlll/S pathway during early ..,o"",orr. 
both ischaemia and v ... r.uUl<u".vnJ/SL..,"'L induced pre:co]nm 
section, we demonstrated STAT-3 activation is during the 
."".....,,,...,'"' and TNFa preconditioning stimuli for cardioprotection to occur. In 
we show that this protection occurs independently to the activation of the 
pathway during the in TNFa-induced pre:cOlnOl.._......,..,. Akt 
is found to be phosphorylated 	 during early following 
both ischaemic (Hausenloy et al. and pharmacological et 2001; 
et al. 2002) preconditioning. In addition, its inhibition early phase 
attenuates the 	 protection by ischaemic preconditioning (See review 
(Hausenloy et al. 	2004c»). 
in this section we to investigate 
The role of STAT-3 and during early reperfusion ischaemia, hypoxia 
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Figure 59: Hypothesis: The role of STAT-3 and Akt during early 
reperfusion in ischaemia- and TNF-induced PC. JAK2- janus kinase 2, 
mTOR- mammalian target of rapamycin, PI3K- phosphotidylinositol-3-kinase, 












2.1 Isolated mouse cardiomyocytes 
protocol to isolate cardiomyocytes is described in section C 2.4. Isolated 
myocytes were exposed to either simulated ischaemia, preconditioning with 
hypoxia or TNFa as described in section C . Pharmacological inhibition of the 
PI3KJAkt pathway was achieved with wortmannin (lOOnmoIlL) or rar:larr:lyc:m 
(O.Snmol/L) (Figure 60) added at the onset reoxygenation In both 
preconditioning groups (Figure 60). Inhibitors were used at previously 
concentrations (Section E 1). Similarly, STAT -3 activation was 
inhibited with AG490 (lOOnmollL) administered at onset of reoxygenation in 
hypoxic preconditioning TNFa-induced preconditioning (Figure 60). 
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Figure 60: Tissue culture protocols for isolated cardiac myocytes. In all 
cells were subjected to an index simulated ischaemia for 26 
hours and 2 hours of Cells were preconditioned with either 30 
minutes of or low dose (0.5ngjml) TNFa followed a 1 hour washout 
period to the index ischaemia. Myocyte cell viability was measured at the 
end of each via trypan blue exclusion. The AG490, 












Isolated perfused rat hearts 
adult, rats (250 to 300g) were rapidly and 
perfused retrogradely by the Langendorff technique as described in section E 
All were subjected to 30 minutes of "'......" ...... '''''VH'~''''' by occlusion the 
left coronary artery 120 minutes of reperfusion. Hearts were preconditioned 
with either preconditioning or dose (0.5nglml) as described 
previously (see Section E and the inhibitors, AG490 (1 OOnmoIlL) , 
wortmannin (lOOnmoI/L) or rapamycin (0.5nmoIlL) were given for the first 15 
minutes of .............1'1 only (Figure 61). size was determined as described 
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Figure 61: Rat heart Langendorff perfusion protocols. In all experiments, 
the index ischaemia lasted for 30 minutes and the final reperfusion time was 
120 minutes. Ischaemic preconditioning was conferred by 2 times 5 minutes of 
ischaemia and reperfusion prior to the index ischaemic insult. TNFa was 
administered for 7 minutes followed by a 10-minute washout prior to the index 
ischemia. The inhibitors AG490, rapamycin and wortmannin were infused for 
the first 15 minutes of reperfusion. Infarct size was measured at the end of 
each protocol via TIC staining. 
2.3 Western blot analysis 
Control or preconditioned rat hearts were subjected to 30 minutes of regional 
ischaemia and 5 minutes of reperfusion. At the end of reperfusion, the ventricular 
tissue at risk was excised and freeze clamped in liquid nitrogen before being 
stored at -80°C. Cytosolic proteins were extracted as described previously section 
E 2.3. Phosphorylated states of Akt (phospho-Ak; serine 473) and STAT-3 











actin were resolved by sodimn dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and were transferred to PVDF membranes by 
electrophoretic transfer. Equal loading was verified by Ponceau staining or ~­
actin, and phosphorylated levels of proteins were normalised to their total protein 
levels in the same samples and under the same conditions but on a separate 
membrane. Relative peptide levels were measured using densitometric analysis 
with UVI band (UVI Tech, Cambridge UK) software on a personal computer. 
2.4 Pharmacological agents and anti-bodies 
Recombinant murine TNFa was obtained from Peprotech Inc (Rocky Hills, NY). 
Anti-bodies for phospho-Akt, phospho-STAT-3 and total Akt were obtained from 
Cell Signalling and anti-bodies for total STAT-3, ~-Actin and all secondary anti­
bodies were obtained from Santa Cruz (Santa Cruz Biotech, CA, USA). All other 
reagents were obtained from Sigma Biochemicals (St. Louis, Mo, USA). 
2.5 Statistical analysis 
Results are expressed as mean values ± standard error of the mean (S.E.M.) and 
were analyzed by one-way ANOVA with Dunn's post-test, using GraphPad InStat 
version 3.01 (Graphpad software, San Diego, California, USA). Differences were 












3.1 	 Inhibition of STAT-3 activation during early reperfusion abrogates the 
protection due to ischaemic and TNFa-induced preconditioning 
To investigate the role of STAT-3 at the time of reperfusion in hypoxic (isolated 
mouse cardiomyocytes), ischaemic (isolated rat heart) and TNFa-induced 
preconditioning (both models) we administered AG490 at the time of reperfusion. 
As reported previously in section C, myocytes cell viability was 55.9±1.9% 
following index ischaemia (Figure 62). Both hypoxia- and TNFa-induced 
preconditioning improved myocytes viability to 88.5±3.6% and 83.0±3.6% 
respectively (p<O.OOI vs simulated ischaemia for both preconditioning stimuli; 
n>6) (Figure 61). AG490 administration inhibited the cardiac protective effects of 
both hypoxic and TNFa-induced preconditioning in isolated cardiomyocytes 
(myocyte viability 49.1±7.5% and 62.7±8.5% respectively; p<O.OOl vs simulated 



















Figure 62: The Role of STAT-3 during early reperfusion in hypoxia- and 
TNFa-induced preconditioning in isolated mouse cardiomyocytes. STAT-3 
activation was inhibited with AG490 added during the 2 hours of reperfusion in 
both the hypoxia or TNFa preconditioned groups. This abrogated the protection 
due to both hypoxia- and TNFa-induced cardioprotection (***p<O.OO 1 vs control, 
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Figure 63: The role of STAT-3 during early reperfusion ischaemic and 

TNFa-induced preconditioning in the isolated rat heart. Inhibition of 

STAT-3 with AG490 during early reperfusion abrogates the protection due to 

ischaemic and TNFa-induced preconditioning (***p< 0.001 vs control, n~6). 

IPC- ischaemic preconditioning. 

Western blot analysis of STAT-3 phosphorylation performed in tissue collected 
after 5 minutes of reperfusion in the isolated rat heart showed an increase of 
STA T-3 phosphorylation in both the ischaemic and TNFa preconditioned groups 
(Figure 64A). However, this increase was reversed following the addition of 
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Figure 64: STAT-3 phosphorylation during early reperfusion. Densities 
expressed in Arbitrary Units (AU) show that STAT-3 is activated during early 
reperfusion following an ischaemic or TNFa preconditioning stimulus (A) . This 
activation is inhibited with AG490 (B) (A: **p<O.Ol vs control, B: *p<O.05 vs 











3.2 Inhibition 	of Akt activation at reperfusion abrogates the protection due to 
ischaemic preconditioning but not TNFa-induced cardioprotection 
To study the role of the PI3K1Akt pathway, we determined myocytes viability 
following inhibition of the PI3K1Akt signaling pathway (wortmannin was used to 
inhibit PI3K and rapamycin was used to inhibit mTOR kinase) at reoxygenation in 
isolated myocytes following hypoxia- or TNFu-induced preconditioning. When 
wortmannin or rapamycin was given at the onset of reoxygenation in hypoxic 
preconditioned cardiomyocytes, the cardioprotective effect was lost (myocytes 
viability 45.3±9.8% and 42.1±5.1 % respectively; ***p<O.OOl vs hypoxia-induced 
preconditioning; n~5) (Figure 65). In contrast, wortmannin and rapamycin failed 
to reverse the protection afforded by TNFu (96.3.0±6.6% and 78.4±5.7% 
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Figure 65: The Role of the PI3KIAkt pathway during early reperfusion in 
Hypoxia- and TNFa-induced preconditioning in isolated mouse 
cardiomyocytes. Inhibiting the activation of Akt with wortmannin (W) or 
mammalian Target of Rapamycin (mTOR) with rapamycin (R) during early 
reperfusion prevented the protection due to hypoxic preconditioning in isolated 
cardiomyocytes. In contrast, TNFa-induced protection was not abrogated 
(***p<O.OOl vs control, n~5, # ns vs TNFa, n~5). HPC- hypoxia-induced 











Similar results were observed in the isolated rat heart with ischaemic 
preconditioning and TNFa. inducing cardioprotection (***p<O.001 vs control, 
n26) (Figure 66) and wortmannin and rapamycin abrogating the protective effect 
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Figure 66: The role of the PI3K!Akt pathway during early reperfusion 
ischaemic and TNFa-induced preconditioning in the isolated rat heart. 
Inhibition of Akt during early reperfusion abrogates the protection due to 
ischaemic but not TNFa-induced preconditioning (***p< 0.001, n~6). IPC­











3.3 Hypoxia but not TNFa triggers Akt activation 
We examined if Akt was phosphorylated during early reperfusion in ischaemic 
and TNFa-induced preconditioning. Ischaemic preconditioning increased Akt 
phosphorylation (from lOO.O±3.0AU in the ischaemic control to 134.0±5.8AU in 
ischaemic preconditioning, **p<O.Ol vs control; n=6) following 5 minutes of 
reperfusion in the rat heart. In contrast, TJ'1Fa did not affect the phosphorylation 
of Akt (Figure 67). 
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Figure 67: Akt activation during early reperfusion. Densities expressed in Arbitrary 
Units (AU) show that Akt is phosphorylated during early reperfusion following an 














Using models species, our novel data apparently for 
the first that cardioprotection at by TNFa is independent 
activation the pro-survival kinase Akt of the RISK pathway) (Hausenloy 
et al. 2004c). More we have shown the existence an alternative 
protective pathway that involves activation of transcripti on 
the time of reperfusion .."''',........... ,'"'''' to both and ischaemic preconditioning. 
The leading to conclusions are as foHows: 
1. TNFa-induced preconditioning did not phosphorylate kinase Akt at the 
time reperfusion. 
2. inhibitors of given during reperfusion did not inhibit 
protection by TNF a. 
3. classic preconditioning phosphorylated STAT-3 >O;'v1 ........... 

early ..",...",..1tl1 
4. Addition of the inhibitor AG490 abolished the protection afforded by 
both ischaemic preconditioning as preconditioning stimuli. 
As already mentioned section E, concept multiple pathways in 
preconditioning has already been suggested in relation to the trigger (see 
review Yellon et (Yellon et al. 2003)). the early of 
rep,ertuslon. it is now well established ischaemic pre~co:nal"Vj'll.J'"," the 
RISK pathway (Tsang et al. 2004; Hausenloy et al. 2005). In addition, many 
pharmacological such as agonists, bradykinin, atorvastatin, 











pathway given at beginning of ypnpyh (Hausenloy et al. 2004c). 
However, now for the to our knowledge, we found that a 
pharmacological preconditioning agent (TNFa) could confer cardioprotection 
independently of activation the RISK pathway during early reperfusion. By 
contrast, we found that an and is activated 
by both classic ischaemic preconditioning and TNFa preconditioning. This novel 
pathway requires phosphorylation ofSTAT-3 at the time ofreperfusion. 
In section we have demonstrated the role during trigger phase in 
both preconditioning (Smith et al. 2004) and ischaemic preconditioning 
not early phase. we have demonstrated 
that acts as a classic lsc.nat::ml preconditioning (Smith et 
2002), we now postulate that ischaemic preconditioning STAT-3 via 
TNFa. However, further experiments will required to determine whether 
STAT-3 may be activated a manner m 
preconditioning. Our data with different pharmacological inhibitors suggest that 
Akt STAT-3 are all ",""''-'UI.,"1 for cardioprotection at reperfusion and 
activation these 2 cOlno~:me:nts IS to a postulated threshold 
protection ischaemic preconditioning. Inhibiting one components 
means that the threshold protection cannot be reached. As an example, 
et al (Hausenloy et al. 2004b) shown that inhibiting Akt at the 
time reperfusion with wortmannin blocks ischaemic preconditioning, even 
the activity of ERK is not inhibited. experiments demonstrated that, 
although is not a component of a pathway nor is it downstream of 











Akt is not ess:en1tlal to reach threshold for protection by Of note, 
experiments that we conducted in our Institute also demonstrated that, 
unlike • .,~.....""'. preconditioning, TNFa-induced cardioprotection is independent 
of the activation ERK at the time early reperfusion (Lecour et al. 2005). 
Another possibility would be that STAT -3 is a downstream target of and/or 
TNFa could directly activate STAT-3, ....,,""'.... ,,"UJ,.., preconditioning 
would activate via and/or Akt. investigations will be 
required to determine exact or cross-talk between different 
pathways. However, based on the results that we have obtained in section E and 
based on the work that has described by Gross et al (Gross et al. 2006) 
during the trigger we can postulate that STAT-3 activation mediate 
Akt activation, during early reperfusion phase following an ischaemic 
preconditioning protocol. 
Although BAD, BAX, p70S6K and eNOS to be downstream 
components responsible for mediating protection associated with 
the RlSK pathway at time (Hausenloy et at. 
2004a) the cell components activated by the RlSK-independent pathway 
stiB remain to be determined. Work that we have performed in our laboratory 
delineates the inhibition of the apoptotic promoting factor as one of the 
components responsible for mediating protection at reperfusion is 
associated with the activation of (Lecour et al. 2005). Many the anti­
apoptotic pathways by prosurvival converge to the 
mitochondria. et al (Juhaszova et al. 2004) have recently shown that 











We previously that pharmacological preconditioning with ..",,...,,>'1",:><'1 
involves the mitochondrial potassium (Lecour et 
2002). It would be to investigate whether activation, 
RlSK pathway, confers protection by preventing the mitochondrial permeability 
transition pore now postulated to be the end of ischaemic 
preconditioning (Hausenloy et al. 2002; et at. 
the present study aelno:nstratl~s pharmacological preconditioning 
induced by TNFa does not require activation of the pathway at 
reperfusion. Moreover, we provide evidence for an alternative protective pathway 
the of STAT-3 Delineating 
exact pro-survival components involved in this 
well as a possible link between these two pathways, is current interest, as it 
may potential therapeutic significance in the mitigation of reperfusion­
induced damage. 
early .."'.... ""..;Cl1 























Ischaemic eccmOltl(]lmrlg was first In 1986 as a procedure giving 
powerful protection against myocardial infarction (Murry et al. 1986). Despite 
research, cellular pathways and In 
protective phenomenon not been fully clarified (Yellon et al. 
nor is it clear whether they converge mechanistically (Reusch 2004). 
TNFa is a pleiotropic cytokine in a dose- time-dependent manner 
mimics ischaemic preconditioning (Lecour et al. 2002). is a transcription 
factor mediating intracellular that is initiated at the cytokine cell 
surface ''''''''''IJ''~' and can activate pro survival pathways. 
further understand the "'16"I""j'U"'5 mechanisms of cardiac preconditioning, we 
aimed to explore of signalling pathway both ischaemic 
TNF a-induced preconditioning. 
The and novel findings presented in this thesis are as follows: 
1. Cre-LoxP technology can used to successfully create cardiomyocyte specific 
STAT-3 knockout (KO) mice. 
2. Genetic depletion cardiac disrupts intracellular 
signalling pathways of ischaemic and pharmacological preconditioning and 
its cardioprotective Furthermore, cardioprotection by"'....)"""''''" 
reperfusion is also lost the STAT-3 KO mice. 
3. STAT-3 phosphorylation required both trigger and ......'''''."...... 











4. In contrast to ischaemic preconditioning, mFa-induced preconditioning does 
not require Akt phosphorylation during the trigger or mediator to 
cardioprotection. 
5. During preconditioning, activation Akt IS dependent 
JAK/STAT-3 pathway. 
In summary, we have shown the existence of an alternative protective pathway 
that involves activation of the transcription STAT-3 reSPOltlSe to both 
ischaemic and mFa preconditioning. In addition, we have shown for first 
cardioprotection with preconditioning can occur independently of 
activation of the prosurvival AU",""",", Akt. We suggest JAK2/STAT-3 is a 
regulator Akt in ischaemic preconditioning. 
Study Limitations 
substantial this was done on STAT-3 KO mice. challenge 
using data solely from KO animals is that genetic depletion of may 
modify cardiac development or function of heart. further 
characterisation of this KO mouse model is required. A detailed 
metabolic analysis STAT-3 KO hearts, both and older mice, is 
required to determine if the loss of cardioprotection may result from metabolic 
deficiencies. STAT-3 has been to carbohydrate metabolism (Inoue 
et al. 2004) and we can speculate the ""F,,,.......vu of carbohydrate metabolism 
KO mouse may be impaired. a ........uu'",.... 
analysis of wild-type and STAT -3 KO mice hearts will required to determine 











susceptibility to disease has reported in cardiac 
" .... 'V"u." STAT-3 KO with advanced (Jacoby et at. 2003). 
To supplement data STAT-3 KO we used the pharmacological 
AG490 to inhibit phosphorylation. inhibitor binds to JAK2, 
STAT-3 phosphorylation. Similarly, inhibits PI3K 
AU"""'~·'"'''' Akt phosphorylation. These two inhibitors do not target directly the 
....."',~"'''... " of interest. inhibitors of proteins are our 
and better delineate the cross-talk between Akt STAT -3. However, 
are not available An alternative approach is the use the 
interference acids technique et at. 2006) or over­LV""BU''''I'''I''' 
expression of mutant dominant forms of within cardiomyocytes 
(Zhang et at. 2005). Based on our findings and the literature, we can speculate 
that direct, pharmacological, activation STAT -3 will lead to cardioprotection. 
This can be with the use of oVler-(~xJllre~;slrLg mIce et at. 
2001). 
models we have this study are both ex vivo of 
ischaemiaJreperfusion injury. models t'PrI,t'P(1pnf limitations do 
not take into account the intracoronary activation of leukocytes, which may 
interfere pathways. It is important to these results an in vivo 
mouse model of cardiac ischaemiaJreperfusion and whether 
genetic ablation and pharmacological inhibition STAT-3 aorogaltes ischaemic 












STAT-3 is required for the transcriptional control of many proteins. To ".A\"H"~J 
these proteins a proteomic study basal and preconditioned KO mice is 
required. Target proteins for analysis include metallothionein-l and 2 (Oshima et 
al. 2005). superoxide dismutase (Negoro et al. 2001) and Bcl-2 
family of proteins (Hattori et al. 2001). proteins have linked with the 
protection induced by activation. In addition, mitochondrial 
permeability transition (MPTP) is currently thought to be the effector 
cardiac preconditioning by Hausenloy et al (Hausenloy et al. 2002». 
A of the STAT-3 depletion on mitochondrial 'n"'.....u'v. and the 
may provide a common end effector of both JAK2/STAT-3 and 
PI3KJAkt signalling pathways. 
The data described in this thesis demonstrates as an important 
protein in cardiac Dn:~COnQl.tlom However, the clinical setting of acute 
myocardial infarction, unpredictability of as ischaemic event prevents the 
successful application of preconditioning. Recently, Vinten-Johansen et al «Zhao 
et al. 2003) have described a new cardioprotective phenomenon known as 
postconditioning. Postconditioning is a form of reperfusion' whereby the 
ischaemia/reperfusion cycles conditioning the heart are applied 
immediately after index ischaemia. Similar to """''''''''''',,''' preconditioning, 
ischaemic postconditioning limits the resultant infarct (Zhao et al. 2003). 
Since it was first described in canine heart model of ischaemia/reperfusion, 
postconditioning has been successfully applied as a mean of 











(Iliodromitis et al. 2006) models. More recently, ischaemic postconditioning has 
been applied clinically (Staat et 2005; Loukogeorgakis et al. 2006). Compared 
to preconditioning, ..".... B postconditioning a more attractive clinical ......' .. 
potential and has therefore become a new focus research and attention. Thus 
studies the signalling mechanism of ischaemic postconditioning have 
revealed similarities between ischaemic preconditioning and postconditioning. 
For Yell on et al have identified the (Reperfusion Injury 
,-,'".I,lL""'" pathway comprising of Akt and ERK 112 activation) as a point of 
convergence for the cardioprotective phenomena of ischaemic preconditioning 
postconditioning (Hausenloy et al. 2005). Therefore, our future 
experiments will aim to explore the role STAT-3 in postconditioning as it may 
have an important application for the development of future drugs to protect 
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